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ABSTRACT 
 
Background: Migraine headache is a chronic pain condition that affects 20% of 
women of reproductive age, and is often treated with triptans. Triptans are 
serotonin 1B, 1D, and 1F receptor agonists that act as vasoconstrictors and 
inhibitors of the trigeminal cervical complex as well as peripheral neurons; they 
cross the blood brain barrier and placenta, and as such are plausible 
neurodevelopmental teratogens. No studies have examined risk of 
neurodevelopmental problems in children with prenatal triptan exposure. This 
dissertation had three aims: (1) to examine risk of behavioral problems in 
children using in the presence of time-varying confounding by concomitant 
medication use; (2) to examine risk of temperamental, motor, and communication 
disturbances associated with prenatal triptans exposure, adjusting for 
unmeasured confounding by migraine type and severity; and (3) to examine 
changes in neurodevelopment over time associated with prenatal triptan 
exposure. 
Methods: This dissertation used data from the Norwegian Mother and Child 
Cohort Study, a prospective birth cohort including more than 100,000 women 
recruited during their first prenatal ultrasound visit. Aims 1 and 3 used marginal 
structural models to assess the risk of (1) neurodevelopmental problems at age 
36 months (Aim 1), or (2) change in risk of neurodevelopmental problems from 
18 to 36 months (Aim 3) associated with prenatal triptan exposure. Aim 2 used 
propensity matching and calibration to adjust for unmeasured confounding by 
migraine type, severity, and attitudes towards medication use in pregnancy. 
Neurodevelopmental outcome measures included the Child Behavior Checklist 
(CBCL), the Emotionality, Activity, and Temperament Scale (EAS), and the Ages 
and Stages Questionnaire (ASQ). Exposure to triptans was ascertained by self-
report. 
Results: Prenatal triptan exposure was associated with greater externalizing 
behavior problems at 18 and 36 months, as well as greater increases in 
emotionality and activity from 18 to 36 months. We observed no association 
between triptan exposure and motor skills or communication problems; triptan 
use during pregnancy was associated with migraine severity but not migraine 
type, and adjustment for unmeasured migraine characteristics moved effect 
estimates towards the null. 
Conclusions: Prenatal triptan exposure is associated with externalizing-type 
behaviors and temperament in children, while migraine itself is associated with 
internalizing-type behaviors and temperament. The use of concomitant 
medications and the severity of the underlying condition both exerted substantial 
influence on observed effect estimates, and should be considered in any future 
studies of triptan medication use in pregnancy.  
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I.1 Medication use during pregnancy 
The use of prescription medications during pregnancy has increased 
dramatically in recent years, not only in the United States but worldwide as well. 
Prevalence estimates from the National Birth Defects Study and the Slone 
Epidemiology Center Birth Defects Study found that by 2008, approximately 70% 
of women in the United States (US) used at least one prescription medication 
during pregnancy, and that the proportion of women who took four or more 
medications increased 2.6-fold in 30 years.1 Additionally, a study based in the 
Health Maintenance Research Network Center for Education and Research on 
Therapeutics found that a medication other than a vitamin or mineral supplement 
was prescribed in 64% of pregnancies, and that more than 40% of these 
prescriptions were for medications classified by the Food and Drug 
Administration (FDA) as belonging to category C, D, or X,2 categories indicating 
possible or probable harm to exposed fetuses. Analgesic medications are the 
third most commonly-prescribed therapeutic class, after anti-infectives and 
respiratory treatments, and are used in nearly 20% of pregnancies.2 Prevalence 
estimates of prescription medication use during pregnancy in countries other 
than the United States suggest a similar secular increase, although overall rates 
tend to be lower.3 Rates of prescription medication use during pregnancy are 
highest during the first trimester,2 a finding that is likely in part attributable to the 
fact that nearly half of all pregnancies in the United States are unplanned.4 
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Studies of the effects of prenatal exposure to prescription medications 
most often focus on immediate pregnancy and delivery outcomes such as 
miscarriage/spontaneous abortion, congenital malformations, low birth weight, 
pre-eclampsia, and preterm birth, while far fewer studies have examined long-
term outcomes, such as neurodevelopment. 
 
I.2   Migraine headache during pregnancy 
Migraine headache is a debilitating condition that most frequently affects 
women: in surveys of the United States population, prevalence of migraine is 
approximately 18-22% in women of reproductive age.5,6 Among migraineurs, 
nearly one third experience attacks severe enough to require bed rest.5 
Pregnancy alters migraine attack frequency and severity: approximately 2 in 3 
women experience the same or worsened severity during pregnancy, while 1 in 3 
experience improvement in their symptoms.6,7 However, this effect attenuates in 
multiparous women.6 By contrast, between 1.3% and 18% of women experience 
their first migraine episodes during pregnancy,7 and higher parity is associated 
with increased risk of migraine over the life course.8  
 Treatment options for migraine are primarily pharmacologic, and include 
both preventive medications as well analgesic medications, which are taken in 
response to an oncoming migraine episode. Preventive medications include β-
blockers, antiepileptic drugs, angiotensin II receptor blockers (ARBs), 
angiotensin-converting enzymes (ACE) inhibitors, and calcium channel inhibitors. 
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Analgesic medications used for migraine include both prescription and over-the-
counter (OTC) drugs, including acetaminophen, NSAIDs, opioids, muscle 
relaxants, ergot alkaloids, and triptans. Among the analgesic medications, 
triptans, a class of serotonin 5-HT1B, 5-HT1D and 5-HT1F receptor agonists, are 
the most common prescription migraine medication given for acute treatment of 
migraine.9 There are seven triptans commercially available worldwide: 
sumatriptan, zolmitriptan, naratriptan, rizatriptan, almotriptan, eletriptan and 
frovatriptan. 
 
I.3 Safety of triptans during pregnancy  
 Triptans are considered a Category C medication by the FDA, indicating 
that animal studies have demonstrated a risk to the fetus associated with 
exposure, but that no adequate and well-controlled trials exist in pregnant 
women. To date, ten studies, including a total of more than 6,000 exposed 
infants, have examined triptan exposure during pregnancy as a risk factor for 
pregnancy and very early life outcomes. Triptan exposure has been associated 
with increased risk of spontaneous abortion/miscarriage/fetal death,10 congenital 
malformations,[12] and preterm birth/prematurity/gestational age;11–13 however, 
differences in sample size comparison groups have led to conflicting reports. 
Two recent reviews report equivocal findings on the safety of triptans: a recent 
meta-analysis concluded that triptan exposure did not increase the risk for 
malformations or preterm birth, but that triptan-exposed pregnancy had a higher 
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rate of spontaneous abortion, and untreated migraine had a higher rate of 
congenital malformations,14  and a recent review (without meta-analysis) has 
recommended that if use of acetaminophen for acute migraine attack does not 
provide sufficient relief, conservative use of triptans during pregnancy may be 
considered.15 Both studies make note of the fact that much of the current 
literature on triptan safety is limited by the lack of a disease control group; that is, 
that several existing studies do not include a comparison group of migraineurs 
who did not use triptans during pregnancy. 
 Triptans have three main mechanisms of action: they act as 
vasoconstrictors in smooth muscle tissue, and particularly as cranial 
vasoconstrictors; they also inhibit peripheral neuronal activity, and inhibit 
transmission in the trigeminal cervical complex.16 Although much attention has 
been focused on the role of 5-HT1A receptors in the developing brain,17 recent 
evidence has suggest that other receptor subtypes are also important for fetal 
brain programming, including the 5-HT1B and 5-HT1D subtypes activated by 
triptans.18–20 The disruption of 5-HT1B/5-HT1D signalling during fetal brain 
development resulted in abnormal thalamocortical neurons.18 The thalamocortical 
pathway has previously been identified in neuroimaging studies as a brain 
network associated with attention-deficit/hyperactivity disorder (ADHD).21 In 
addition, triptans are small, lipophilic molecules that readily cross the placenta 
and the blood-brain barrier. As such, triptans are plausible neurodevelopmental 
teratogens; however, no prior studies have examined the  
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neurodevelopmental sequelae of fetal exposure to triptans. The etiology of  
childhood neuropsychiatric and neurodevelopmental disorders is not well 
understood, although children are at higher risk if born to a parent with 
neuropsychiatric illness.22,23 In addition, rising rates of childhood-onset 
neuropsychiatric disorders, developmental delay, and related conditions put a 
substantial financial burden on families and the healthcare and educational 
systems in the US.24,25 Understanding potential risk factors for 
neurodevelopmental disorders, particularly modifiable risk factors such as 
medication exposure during pregnancy, could provide important insights into the 
causes of these disorders. 
 
I.4 Methodological challenges 
 Studying the safety of triptans during pregnancy requires careful 
consideration of several complex confounding problems. First, it is necessary to 
consider the role of the underlying condition, migraine, as a possible cause for 
any observed differences between children with prenatal triptan exposure and 
those unexposed. Confounding by indication is a form of bias that is notoriously 
difficult to adequately control.26 Migraine itself may be an independent risk factor 
for neurodevelopmental problems: migraine shares genetic susceptibility with 
several psychiatric disorders, including depression and anxiety.27,28 Because 
these disorders are themselves heritable, and often have their origins in early 
childhood,29 failing to consider migraine characteristics, including type and 
   
 7 
severity, could lead to incorrectly attributing an effect to triptans that more 
properly belongs to the condition for which triptans were prescribed. 
 Second, women who take triptans during pregnancy also take many other 
medications, including both antidepressants and acetaminophen, both of which 
have previously been associated with neurodevelopmental problems in 
children.30–33 In addition, triptans are taken episodically, in response to impending 
migraine onset: a women with migraine may take a triptan once, many times, or 
not at all over the course of her pregnancy. Similarly, use of other analgesic 
medications will also vary over time: these other medications are simultaneously 
confounders (common cause exposure and outcome) and mediators (on the 
causal pathway between exposure and outcome). Failure to adjust for 
concomitant medication may result in estimates biased further from the null, 
while adjusting for these medications can results in unpredictable bias. As a 
result, the case of time-varying exposure with time-varying confounding requires 
special consideration. 
 Finally, while studying child neurodevelopment at a single time point is 
important, the best understanding of neurodevelopment comes from considering 
the trajectory over time. Brain development begins in the first trimester of fetal 
life, but it continues throughout childhood and into early adulthood. If differences 
in neurodevelopmental outcomes exist between children with and without 
prenatal triptan exposure, understanding differences in trajectory over time may 
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yield important insights into the mechanism by which triptans affect the 
developing brain. 
 
I.5 Summary 
Understanding the possible risks of medication exposure during 
pregnancy of necessity relies upon the use of observational data, as pregnant 
women are routinely excluded from randomized clinical trials for ethical reasons. 
Studies of the safety of medication use during pregnancy, therefore, must 
carefully balance the need for accurate risk estimates against the potential for 
falsely alarming women and prescribers, and thereby depriving women of 
needed medications. The purpose of this dissertation is to apply causal inference 
techniques and other methods to obtain unbiased estimates of the effect of 
prenatal triptan exposure on neurodevelopment in children. The findings from this 
work will have implications for clinicians who treat pregnant women with migraine 
headache. 
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CHAPTER II 
 
PRENATAL TRIPTAN EXPOSURE INCREASES EXTERNALIZING 
BEHAVIORS AT THREE YEARS: RESULTS FROM THE NORWEGIAN 
MOTHER AND CHILD COHORT STUDY 
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II.0  Abstract 
Background.  Triptans are serotonin agonists given for the acute treatment of 
migraine, a chronic pain condition that is highly prevalent in women of 
childbearing age. No previous studies have examined associations between 
prenatal triptan exposure and neurodevelopment in children. 
Methods.  This questionnaire-based study was set in the Norwegian Mother and 
Child Cohort study, a prospective birth cohort that includes nearly 40% of all 
pregnancies in Norway from 1999-2008. 41,173 live, singleton births without 
major malformations who responded to the 36-month post-partum follow-up 
questionnaire were included in this study, of which 396 used a triptan during 
pregnancy, 798 used a triptan prior to pregnancy only, 3291 reported migraine 
without triptan use, and 36,688 reported no history of migraine or triptan use.  
The Internalizing and Externalizing subscales of the Child Behavior Checklist 
were the main outcome measures for this study.  We employed a cutoff score of 
T>65 to indicate symptoms that were present at clinically relevant levels. 
Results.  Children exposed to triptans during pregnancy had a 1.39-fold 
increased risk of externalizing behaviors compared to those whose mothers used 
triptans prior to pregnancy only (95% CI: 0.97 to 1.97), a 1.36-fold increased risk 
compared to the unmedicated migraine group (95% CI: 1.02 to 1.81), and a 1.41- 
fold increased risk compared to the population comparison group (95% CI: 1.08 
to 1.85). The greatest risk was associated with first trimester exposure (RR: 1.77, 
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95% CI: 0.98, 3.14).  Risk differences were small, ranging from 3-6%. No 
association was observed between triptan exposure and internalizing behaviors. 
Conclusions. This study found an increased risk of clinically-relevant 
externalizing behaviors in children with prenatal exposure to triptans, and this risk 
was highest for first trimester exposure.  However, absolute risks were small, and 
the results may be due to confounding by underlying migraine severity. 
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II.1     Introduction 
Migraine headache, characterized by debilitating pain and significant 
disability, affects between 18% and 22% of women and is most common in 
women of childbearing age.5,6 Treatment for migraine is primarily pharmacologic 
including prescription medications (e.g., triptans, opioids) and over-the-counter 
medicines (e.g. acetaminophen and non-steroidal anti-inflammatory drugs 
(NSAID)). The European Federation of Neurological Societies (EFNS) 
recommends no triptan use during pregnancy unless the developing fetus is at 
great risk from the untreated maternal migraine,34 while the Food and Drug 
Administration (FDA) has assigned triptans a C-category rating,7 suggesting lack 
of evidence for both maternal and fetal safety. This lack of safety data leaves 
women and prescribers with uncertainty and may result in under-treatment of 
severe pain. Pregnancy outcomes following exposure to triptan medications have 
been studied prospectively.12,35–37 No increased risk of congenital malformations 
was observed, although several studies noted an increased risk for poor 
pregnancy outcomes, including pre-eclampsia or hypertension, preterm birth, 
atonic uterus, and folate-deficient anemia.12,37 To our knowledge, no studies 
have examined neurodevelopment following prenatal triptan exposure. 
Neurodevelopmental outcomes, such as internalizing symptoms, 
characterized by inward emotional states (e.g. depression, shyness, anxiety) and 
externalizing symptoms (e.g. aggression) are important outcomes to study.  
Internalizing symptoms are predictive of future anxiety disorders38 and panic 
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attacks,39 and externalizing behaviors predict future depression and disruptive 
behavior.38 Triptans are serotonin 5-HT agonists that act both as vasoconstrictors 
and inhibitors of the trigeminocervical complex,40 and are thought to cross the 
blood-brain barrier.41 Serotonin is involved in all stages of neurodevelopment.17 
Other pharmacologic agents that effect serotonin homeostasis, such as selective 
serotonin reuptake inhibitors, have been associated with an increased risk for 
autism spectrum disorders42,43 and attention-deficit/hyperactivity disorder44,45 in 
children.  
Understanding potential risk factors for neurodevelopmental disorders 
could provide important insights into the causes of these disorders. This study is 
set in the Norwegian Mother and Child Cohort Study, a prospective birth cohort 
with information on prescription and over-the-counter medication use over time 
during pregnancy. The aim of this study was to investigate the possible 
association of prenatal triptan exposure and behavioral problems in three-year-
old children, using causal inference methods. 
 
II.2     Methods 
Study Sample 
The Norwegian Mother and Child Cohort Study (MoBa) was established 
by the Norwegian Institute of Public Health and recruited participants from 1999-
2008.  Women were invited to participate prior to routine ultrasound 
appointments (pregnancy weeks 13-17). A total of 108,841 women consented; 
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these women comprise 38.7% of the pregnancies in Norway during the study 
period. Participation rates for the six month post-partum and 36 months post-
partum questionnaires were 84.8% and 60.2%, respectively.46 The MoBa study, 
including participation and retention rates, has been described in greater detail 
elsewhere.47 Written informed consent was obtained from all participants, and the 
study was approved by the Regional Committee for Medical Research Ethics and 
the Norwegian Data Inspectorate; this analysis was granted an exemption from 
the University of Massachusetts Medical School Institutional Review Board.  Data 
were taken from the quality-ensured Data Version 6, released by MoBa in 2012 
and includes all children born before 2009 for whom the age 3 years 
questionnaire was received by May 4, 2011; these data were linked to the 
Medical Birth Registry of Norway (MBRN) using participants’ 11-digit personal 
identification numbers. 
Because this study focused on infant neurodevelopment, we excluded 
infants not born alive (N=680), multiplet births (N=3,801), and infants born with 
major congenital malformations or chromosomal abnormalities (N=3,204); 
further, we excluded women who reported triptan exposure but did not report 
whether exposure occurred prior to or during pregnancy (N=14); in total, 7,220 
pregnancies were excluded, leaving an initial study sample of 101,644 women. 
Comparisons of included and excluded pregnancies revealed that excluded 
women were older, had higher body mass indices (BMI), were more likely to be 
primiparous, and were more likely to have reported using antidepressants or 
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benzodiazepines during pregnancy. At the 36-month follow-up, 41,173 
participants had complete data on the main outcome measure. The flow through 
the study is outlined in Figure 2.1. 
Ascertainment of triptan exposure 
Information on exposure to medications was gathered prospectively from 
two prenatal (Q1, Q3) and one postpartum questionnaire (Q4).  Women were 
asked to indicate when they had taken a medication (during the six months 
before pregnancy, during weeks 0-4, 5-8, 9-12, and/or 13 or later for Q1, during 
weeks 13-16, 17-20, 21-24, 25-28, and/or week 29 or later for Q3, and from week 
30 until birth for Q4), and to write the name of the medication in a text box.  
Women who indicated multiple medications in a single text box (e.g., sumitriptan 
and acetaminophen) were assumed to have been exposed to all listed 
medications in all time periods.  Medications were classified according to the 
World Health Organization Anatomical Therapeutic Chemical (ATC) 
Classification System.48 The ATC code N02CC was used to determine triptan 
exposure. Triptan medications were further classified into specific compounds: 
N02CC01 (sumatriptan), N02CC02 (naratriptan), N02CC03 (zolmitriptan), 
N02CC04 (rizatriptan), N02CC05 (almotriptan), N02CC06 (eletriptan), and 
N02CC07 (frovatriptan).  No information was available on formulation (tablet vs. 
injection or nasal spray) or dose.  Because triptan exposure is relatively rare, 
timing of exposure was collapsed into trimester categories (pre-pregnancy, first 
trimester, second/third trimester, use during pregnancy with unknown timing). No 
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data are available on sensitivity and specificity of triptan medication recall during 
pregnancy; estimates of accuracy of maternal recall of psychotropic medication 
give positive predictive values (PPV) of 85.9%,49 sensitivity of 0.21 – 0.57, and 
specificity of 0.99 — 1.00, while recall of analgesic medication use in pregnancy 
may vary between 0.17 -- 0.41 (sensitivity) and 0.96 -- 0.99 (specificity), 
respectively.50 These values suggest that women may forget medication use, but 
that any reported use is unlikely to be a false positive. 
Ascertainment of outcome 
Internalizing and externalizing behaviors tend to be relatively stable over 
multiple measurements,29 including measurements conducted in early childhood 
predicting problems in adolescence.51 Thus, the Child Behavior Checklist 
(CBCL), a validated measure of child behavior widely used in both clinical and 
research practice, was used to define neurodevelopmental outcomes at age 3 
years.  A shortened version was used in MoBa; this version has been validated in 
a Norwegian population.52 The externalizing (including the “attention problems” 
and aggressive behavior” subscales) and internalizing (including the “emotionally 
reactive,” “anxious/depressed,” and “somatic complaints” subscales) domains 
were used.  Standardized z-scores were computed for the study sample; scores 
were further classified as being clinically meaningful (z  1.50, equivalent to a T 
score of 65).  
Potential confounders and mediators 
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Confounders were identified through literature review and selected 
through iterative use of directed acyclic graphs (dagitty.net). Maternal age, pre-
pregnancy BMI (underweight or <18.5 kg/m2, normal weight or 18.5-25 kg/m2, or 
overweight, >25 kg/m2 according to WHO guidelines), education (primary or 
secondary vs university or higher), marital status (married or cohabiting vs other), 
parity (multiparous vs. primiparous) were all ascertained by self-report on Q1. 
Smoking (ever during pregnancy vs. not during pregnancy) and alcohol use (ever 
during pregnancy vs. not during pregnancy) were ascertained by combining 
information from self-report as well as linkage to the Medical Birth Registry of 
Norway (MBRN). Maternal symptoms of depression and anxiety, were assessed 
using the Symptom Checklist 8 (SCL-8), a short version of the SCL-25.53 The 
SCL-8 is highly correlated with the SCL-25 and has been widely used in surveys 
of mental health.  The SCL-8 is administered via self-report at Q1 and Q3.  
Standardized z-scores were computed at each time point, and an average SCL-8 
score was used in the models. 
Confounding by indication, in which the condition underlying medication 
use is the true cause of the outcome, rather than the medication use itself, is 
important to address when studying medication exposure during pregnancy. 
Because migraine and depression have significant shared genetic 
susceptibility,54 and because migraineurs who take triptans also use many other 
medications, some of which have been associated with neurodevelopmental 
problems in children,30,31 obtaining unbiased estimates of the effect of prenatal 
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triptan exposure on neurodevelopment requires careful consideration of 
underlying disease severity as well as concomitant medication use.  Women 
were specifically asked about history of migraine at Q1 only, and were classified 
as having migraine headache if they indicated had migraines or had taken 
migraine medications.   Migraine headache may be treated with medications 
other than triptans, including analgesics such as aspirin, non-steroidal anti-
inflammatory drugs (NSAID), acetaminophen, and opioids.7 Other medications 
considered as potential confounders were psychotropic medications, including 
antidepressants, benzodiazepines, and anti-seizure medications. The following 
ATC codes were used: N02BE01 (acetaminophen), N02A (opioids), M01A (non-
steroidal anti-inflammatory drugs, NSAIDs), N06A (antidepressants), N05CD02, 
N05CD03, N05CD08, N05BA01, N05BA05, N05BA12 (benzodiazepines), and 
N03A (anti-convulsants). All co-medications were categorized both as ever vs. 
never used in pregnancy and according to timing (pre-pregnancy, first trimester, 
second/third trimester).  Because previous research has indicated an effect of 
acetaminophen dose on child neurodevelopment,30 we also considered 
acetaminophen exposure as a three-category variable: no trimesters exposed, 
one trimester exposed, or two or more trimesters exposed. 
Potential mediators —that is, factors that could be caused by triptan 
exposure and also effect later neurodevelopment—included several intermediate 
pregnancy outcomes: small for gestational age (defined as below the 10th 
percentile for gestational age55), preterm birth (born before gestational week 37), 
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and five minute Apgar score (7 or higher vs <7). Mediators were identified 
through linkage to the Norwegian Medical Birth Registry (MBRN).   
Missing data for important confounders were assessed, and rate of 
missingness was low (<5% missing) as well as nondifferential with respect to 
exposure group.  We elected to conduct a complete case analysis, excluding 
6,856 women who were missing data on at least one confounder (Figure I.1). 
We conducted sensitivity analyses to better understand the possible impact of 
two potential sources of bias: residual confounding by acetaminophen exposure, 
and unmeasured confounding by migraine severity.  To address the former 
concern, we repeated our main analyses in a subgroup of women who did not 
report acetaminophen exposure during pregnancy (n=22581). To address 
confounding by migraine severity, which was not measured in MoBa, two 
approaches were taken. First, we compared the risk of behavior problems 
between different disease exposure groups: a group of women who discontinued 
triptan use prior to pregnancy, a group with migraine headache but no history of 
triptan use, and a population comparison group with no migraine or triptan 
history. These disease comparison groups may be thought of as a proxy for 
migraine severity, and as such, we expected to see a dose-response relationship 
between comparison group and behavioral symptoms, in which the highest risk 
of behavior problems is present in the women who used triptans in pregnancy, 
and progressively lower risks present in triptan discontinuers and women with 
migraine but no triptan history; further, because migraine is associated with an 
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internalizing disorder, depression, we would expect to see a stronger association 
with internalizing rather than externalizing behavior. Second, we used 
probabilistic bias analysis to quantify the possible bias introduced by migraine 
severity, using Excel spreadsheets developed by Lash, Fox, and Fink.56 We used 
prevalence estimates for severe migraine ranging from 0.20 to 0.40, which are 
consistent with recent population estimates,57 and assumed that severe migraine 
was twice as prevalent in triptan users as in women who discontinued triptan use 
prior to pregnancy.  We allowed the association between the unmeasured 
confounder, migraine severity, to vary between 1.25 and 4.00, and conducted 
10,000 simulations for each combination of bias parameters. 
Statistical methods 
Our analysis proceeded in several steps.  First, we estimated the 
prevalence of triptan use overall and by trimester. We then evaluated descriptive 
statistics by triptan use to better understand the population and factors that may 
confound the triptan-neurodevelopmental relationship.  Because co-medication 
use was likely, we examined prevalence of comedication in triptan users and 
non-users throughout pregnancy.  Two modeling approaches were applied:  
Poisson models and marginal structural models. 
Poisson Models 
Modified Poisson models were used to obtain risk ratios and risk 
differences for the association between triptan exposure and clinically significant 
behavioral problems; 95% confidence intervals were calculated using robust 
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standard errors.58 Models were adjusted for maternal age, pre-pregnancy BMI, 
parity, marital status, education, co-medication use (NSAIDs, acetaminophen, 
opioids, and antidepressants), depression/anxiety symptoms, smoking, and 
alcohol use.  Considered individually, none of the confounders changed the 
estimate of effect by more than 10%.  To better understand the effects of timing 
of triptan exposure, we examined the risk of triptan exposure for prenatal, first 
trimester, and second/third trimester exposure within a subsample of women who 
reported a history of migraine headache.   
As part of the sensitivity analyses described above, we compared the risk of 
behavioral problems in children prenatally exposed to triptans to three reference 
groups.  To partially address issues of confounding by migraine severity, we 
identified a group of children whose mothers used triptans in the six months prior 
to pregnancy but discontinued use in pregnancy; we also compared prenatally 
exposed children to children whose mothers reported a history of migraine, but 
did not report any use of triptans during pregnancy or in the six months priors, 
and finally, to a population comparison group whose mothers reported no history 
of migraine or triptan use.  
Marginal Structural Models 
The second modeling approach used was a marginal structural model 
analysis. This allowed us to account for possible effects of time-varying exposure 
and confounding and to determine the extent to which any observed effects of 
triptan exposure might be mediated through intermediate birth outcomes.  Triptan 
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medications are taken in response to an oncoming migraine attack, and as such 
their use will change over time during pregnancy: a migraineur may take a triptan 
only prior to pregnancy, during the first trimester, during later trimesters, or at 
multiple times.  In addition, her use of triptans may be confounded by other 
factors, such as concomitant medication use, which may also change over time.  
For example, first trimester triptan exposure might be associated with second 
trimester acetaminophen use, which in turn could be associated with third 
trimester triptan use (Figure 2.2).  In this case, acetaminophen is both a 
confounder and a mediator: if acetaminophen is associated with increased risk of 
behavioral problems, then failing to adjust for acetaminophen use will cause an 
overestimate of the effects of triptan exposure, but adjusting for acetaminophen 
use will result in a bias of the effect estimate towards the null.  To consider the 
possible scenario in which time-varying confounders are also mediators, we 
performed a marginal structural model analysis using methods described by 
Robins & Hernan59,60 as well as Bodnar.61 We constructed stabilized inverse 
probability of treatment weights (IPTWs) via logistic regression,62 in which 
exposure at each time point (pre-pregnancy, first trimester, second/third 
trimester) was the dependent variable and predictors in the model included 
baseline confounders (maternal age, pre-pregnancy BMI, education, marital 
status), time-invariant confounders (smoking and alcohol use during pregnancy, 
severity of depressive symptoms in pregnancy) and triptan history.  
The stabilized IPTW for each individual i at each measurement occasion t is: 
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where TRP, CON, and TVC are random variables representing triptan exposure, 
baseline confounders, and time-varying confounders, respectively, and trp, con, 
and tvc are the observed values for these random variables for each individual i. 
Overbars indicate the history of each variable up to the measurement occasion t.   
We ruled out the need to truncate the weights at the 99th and 95th percentiles as 
doing so did not substantially alter the results. The MSM approach has the effect 
of achieving balance of confounders within strata of exposure; if the confounders 
are also mediators (see Figure 2.2 for illustration), this approach may reduce bias 
induced by inappropriate control for an effect on the causal pathway.  The MSM 
approach produces unbiased effect estimates if the assumptions of consistency, 
exchangeability and positivity are met, although the reduction in bias also comes 
with an increase in variance.62 While not formally testable, we took steps to 
evaluate whether the assumptions of exchangeability and positivity were met.  To 
strengthen the assumption of positivity, which requires that all individuals in the 
sample have a non-zero probability of exposure, we limited MSM analyses to 
women with a reported history of migraine, reasoning that triptan medications are 
only prescribed for migraine headache, and inclusion of non-migraineurs could 
result in structural zeroes. Unmeasured confounding by migraine severity may 
pose a threat to exchangeability; to examine this, we compared concomitant 
medication use rates of women who took triptans during pregnancy compared to 
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women who discontinued use of triptans, or those who had no history of triptan 
use.  After constructing stabilized weights, we fit a weighted Poisson model with 
robust standard errors to account for clustering induced by weighting. 
We used a SAS macro developed by Vanderweele and Valeri63 to quantify 
the direct effects of prenatal triptan exposure on neurodevelopment, as well as 
the indirect effects of triptan exposure mediated through birth outcomes, 
including birth weight, gestational age, and 5 minute Apgar score; because our 
analyses did not reveal significant indirect effects of triptan exposure through 
individual mediators, we have not included the results of the mediation analyses 
in this report.  All analyses were carried out using SAS version 9.3. 
 
II.3     Results 
 Prevalence of triptan use during pregnancy was 1.1%, and prevalence of 
use prior to pregnancy was 3.0%. 10.9% of women reported a history of migraine 
prior to pregnancy or up to the 13th week of pregnancy (pregnancy questionnaire 
1). Among those women who reported triptan use, 94.6% used triptans prior to 
pregnancy, 25.6% used triptans in the first trimester, and 10.6% reported use in 
the second or third trimesters. Based on self report of medication use and 
migraine history, women were further classified into four exposure groups: triptan 
exposure during pregnancy (N=396), six months prior to pregnancy but not 
during pregnancy (N=798), history of migraine without triptan use (N=3,291), and 
a population comparison group in which no history of migraine or triptan use was 
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reported (N=36,688).  The characteristics of the study sample for these groups 
are outlined in Table 2.1.  Among women with a history of triptan use, women 
who used triptans during pregnancy were slightly older and were more likely to 
be multiparous. In addition, they had higher rates of pre-pregnancy opioids, 
antidepressant, and benzodiazepine use, and were more likely to use opioids, 
acetaminophen, NSAIDs, antidepressants, and benzodiazepines during 
pregnancy, compared to women who discontinued triptan use during pregnancy. 
Descriptive analysis suggested that the four exposure groups we identified had 
distinct medication use patterns over time (Figure 2.4).  Women with a history of 
triptan use also had higher rates of preventive therapy than women with migraine 
but no triptan history. Women who took triptans during pregnancy also had 
higher rates of pre-eclampsia.  Infants prenatally exposed to triptans were more 
likely to be born preterm and to have a five-minute Apgar score below seven. 
Sumitriptan was by far the most commonly used medication, followed by 
zolmitriptan and rizatriptan (Table 2.2). The rank order of medication did not vary 
by time of use during pregnancy. 
Externalizing behaviors 
Externalizing symptoms at or above a clinical cutoff of T>65 were present 
in 11.6% of children exposed to triptans in utero, compared to 8.3% in children 
whose mothers use triptans prior to pregnancy only, 9.1% in children whose 
mothers reported migraine with no triptan use, and 7.7% in a population 
comparison group (Figure 2.3A). Table 2.3 shows that children whose mothers 
   
 27 
used triptans during pregnancy had a 36% increased risk of clinically-relevant 
externalizing behaviors compared to a population comparison group (RRadj: 1.36, 
95% CI: 1.04 to 1.79).  We observed similar risks when comparing children with 
prenatal triptan exposure to children whose mothers reported migraines but no 
triptan use (RRadj: 1.33, 95% CI: 1.00 to 1.78) as well as to children whose 
mothers used triptans prior to pregnancy only (RRadj: 1.36, 95% CI: 0.96 to 1.94). 
The risk of externalizing behavioral problems was highest children exposed to 
triptans in the first trimester (13.2%) and lowest in women reporting use in 2nd 
and 3rd trimester (8.0%) (Figure 2.3B). When we examined risks of externalizing 
behavior associated with windows of exposure to triptans among women with a 
history of migraine (N=4,439), first trimester exposure was associated with a 77% 
increased risk in multivariable-adjusted Poisson models (95% CI: 1.23 to 3.56), 
while no increased risk was observed for pre-pregnancy exposure. Estimates of 
effect from marginal structural models were similar, although 95% confidence 
intervals were considerably wider: first trimester exposure was associated with a 
75% increased risk of externalizing symptoms in the clinical range (RRMSM: 1.75, 
95% CI: 0.98 to 3.14), while pre-pregnancy (RRMSM: 0.99, 95% CI: 0.77 to 1.27) 
and second/third trimester (RRMSM: 0.59, 95% CI: 0.23 to 1.51) exposure showed 
no evidence of increased risk.   
The absolute risk for first trimester triptan exposure was 6% (95% CI: -
0.02 to 0.15), which is equivalent to a number needed to harm (NNH) of 17.   
Internalizing behaviors 
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 Fewer children in our sample exhibited clinically meaningful internalizing 
symptoms than externalizing symptoms (Figures II.3A and B). Comparing 
children born to women who used triptans during pregnancy to those whose 
mothers used triptans prior to pregnancy only (RRadj: 0.78, 95% CI: 0.51 to 1.21), 
those with migraine but no triptan use (RRadj: 0.89, 95% CI: 0.61 to 1.30), and a 
population comparison group (RRadj: 1.02, 95% CI: 0.71 to 1.47) revealed no 
increased risks of internalizing behavior problems in the clinical range; absolute 
risks were zero or near zero for all comparisons (Table 2.4). An analysis of 
women who did not use acetaminophen during pregnancy revealed similar point 
estimates to the main set of analyses; however, the smaller sample size, which 
included only nine triptan-exposed children with externalizing behavior problems 
and six with internalizing problems, resulted in wider confidence intervals that 
included the null (results not shown). Estimates of the effect of triptan exposure 
at specific times revealed inconsistencies between multivariable adjusted 
Poisson models and marginal structural models (Table 2.S1).  Multivariable 
models showed an increased risk of internalizing symptoms associated with pre-
pregnancy (RRadj: 1.27, 95% CI: 1.01 to 1.59) but not during pregnancy; MSM 
estimates showed no association between pre-pregnancy exposure and 
internalizing behaviors (RRMSM: 1.04, 95% CI: 0.80 to 1.35).  Absolute risks were 
near zero, with 95% confidence intervals that included the null. 
Sensitivity Analyses 
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Contrasts between the disease comparison groups (i.e., comparing the 
pre-pregnancy use only group to the population comparison group) revealed risk 
ratios near 1.0 and risk differences near 0.0, indicating no increased risk of 
externalizing symptoms for women with migraine who avoided triptan use or 
discontinued use prior to pregnancy (Table 2.S2).  We observed a 31% 
increased risk of internalizing symptoms in women who discontinued triptans 
prior to pregnancy compared to the population comparison group (95% CI: 1.04 
to 1.65), and a 14% increased risk for the unmedicated migraine group versus 
the population comparison group (95% CI: 1.01 to 1.30), suggesting that the 
underlying illness may increase the risk for internalizing symptoms. 
Probabilistic bias analysis showed that, using bias parameters that we 
considered reasonable based on existing literature (an association between 
migraine severity and externalizing symptoms of RR=1.50, prevalence of severe 
migraine of 40% in triptan users and 20% in triptan discontinuers), the 
association between triptan use and externalizing symptoms were slightly 
reduced (RR: 1.40 vs. bias-corrected RR: 1.29).  To completely explain the 
increased risk associated with triptan use, an association between migraine 
severity and externalizing behavior would have had to have been at least 4.0 
(Table 2.S3). 
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II.4     Discussion  
In this prospective study of prenatal exposure to triptan medication and 
risk of neurodevelopmental problems in three-year-old children, we observed a 
consistent, near-40% increased risk of externalizing behavior problems in the 
clinical range among children born to mothers who used triptans during 
pregnancy, compared to those who used triptans prior to pregnancy only, those 
with migraine but no triptan use, and a population comparison group.  This risk 
seems to be associated primarily with a 75% increased risk for first trimester 
exposure. To place our findings in a clinical context, the risks observed were 
modest, and the absolute risks were small. No increased risk of internalizing 
symptoms was noted, and exposure in pregnancy after the first trimester was not 
associated with an increased risk of either externalizing or internalizing 
symptoms.   
 The increasing prevalence of neurodevelopmental and psychiatric 
disorders in children64,65 poses a serious public health challenge. Identifying 
antecedents of these disorders is vital both for understanding the 
pathophysiologic basis of disease, as well as providing opportunities for 
intervention.  Externalizing disorders in very young children have been shown to 
have high diagnostic stability into school age,29,66 and are predictive of major 
mental illness later in life, including major depression. Risk factors for 
externalizing symptoms, therefore, can give important insights into the origins of 
diseases that result in substantial impairment throughout the life course. 
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 In studies of the risks of prenatal exposure to medication, it is particularly 
important to consider the possible influence of confounding by indication, 
especially when the indication for which the medication was prescribed is 
heritable67 and suspected to have direct effects on fetal development,68 as is the 
case with migraine.  It is likely that women who continue to take a medication 
during pregnancy have a more severe course of migraine than those who 
discontinue its use before or early in pregnancy. In the absence of information on 
migraine severity, which was unavailable in the MoBa study, we have identified 
multiple comparison groups: a group of women who discontinued triptan use 
prior to pregnancy, a group with migraine headache but no history of triptan use, 
and a population comparison group with no migraine or triptan history. These 
disease comparison groups may be thought of as a proxy for migraine severity, 
and as such, we would expect to see a dose-response relationship between 
comparison group and behavioral symptoms, in which the highest risk of 
behavior problems is present in the women who used migraines in pregnancy, 
and progressively lower risks are present in triptan discontinuers and women with 
migraine but no triptan history. Such a relationship is present for internalizing 
symptoms, which might be expected, given previously-described genetic links 
between migraine and depression.69 However, no such relationship was 
observed for externalizing symptoms; rather, we noted a modest but consistent 
elevated risk for prenatal triptan exposure compared to all other comparison 
groups, and no elevated risk for externalizing behaviors in the migraine groups 
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that did not report triptan use. In addition, the results of probabilistic bias analysis 
to determine the possible effect of unmeasured confounding by migraine severity 
suggest that there would need to be a substantial association between migraine 
severity and externalizing behaviors (RR>4.0) to fully explain the observed 
association between triptan exposure and externalizing symptoms.  
 This study is the first to examine risks of neurodevelopmental problems 
associated with prenatal triptan exposure, and has several important strengths.  
First, this study compares triptan exposure during pregnancy to multiple 
comparison groups, including two disease comparison groups, and found a 
moderate but consistent elevated risk for the triptan-exposed group. Second, the 
study is based in a large, prospective birth cohort in which extensive medication 
data were available, including information on use of over-the-counter medications 
such as acetaminophen.  Several recent studies have noted increased risks of 
externalizing and/or ADHD-like symptoms in children prenatally exposed to 
acetaminophen30,31 as well as antidepressants,33 making it particularly important 
to appropriately adjust for these potential confounders. Additionally, this study 
uses advanced causal inference methodology to assess the risks associated with 
prenatal exposure to medications.  While marginal structural models are 
becoming more common in the epidemiologic literature, they have rarely been 
used to evaluate risks of pregnancy medication use.  In the case of 
neurodevelopmental effects of medication exposure, when there is no known 
safe period for exposure, it is important to carefully model both time varying 
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exposure and confounding; failing to do so may result in biased effect estimates.  
In our analyses, the traditional multivariable-adjusted modeling approach 
indicated an increased risk of internalizing symptoms associated with pre-
pregnancy triptan exposure, which was attenuated when proper adjustment was 
applied using marginal structural models, although it is important to note that the 
confidence intervals from the traditional regression-adjusted and MSM results 
overlapped. These innovations are particularly important in light of the high rates 
of concomitant medication use observed among women who took a triptan during 
pregnancy. 
 Our study has several notable limitations, which should be taken into 
account when considering the results.  Although nearly one in four women with 
migraine reported using triptans either prior to or during pregnancy, the overall 
risk of migraine in our sample was lower than expected (10%, versus population 
estimates of 18-22%5,6). While the MoBa sample includes nearly 40% of births in 
Norway during the study period, previous reports have noted that participants in 
MoBa are healthier than the general population.47 Women with more severe 
migraine and higher rates of triptan use may not have participated in this study, 
limiting its generalizability; however, this selection bias is unlikely to have 
produced inflated estimates of effect.70  
Although we have applied several sensitivity analyses to assess the 
potential for confounding by indication, we cannot rule out the possibility that our 
findings may be explained by migraine severity or frequency. Migraine headache 
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is heritable,27,54,69 and is linked to internalizing symptoms in both children and 
adults.68,69 One recent study noted that children with migraine have more severe 
internalizing problems than children without migraine, but that this difference was 
attenuated after adjusting for maternal headache frequency;68 another study 
noted that internalizing symptoms may indicate a prodromal migraine state.71 No 
such effects have been reported for externalizing symptoms. The fact that our 
analysis showed an increased risk of externalizing symptoms should alleviate 
some concern that our findings may be explained by confounding by indication. It 
is also possible that the observed increased risk for externalizing problems after 
triptan use during pregnancy could be due to personality differences between 
women using medication during pregnancy and women abstaining from 
medication during pregnancy. Ystrom et al.72 found that women using 
acetaminophen during pregnancy had lower scores on the personality trait of 
conscientiousness.72 Low conscientiousness is heritable,73 and is a core feature 
of externalizing problems in adults.74 Since externalizing problems are heritable 
already during preschool age,75 the association found between triptan use during 
pregnancy and child externalizing problems could be due to a genetic 
transmission of risk. An additional limitation is that despite the large sample size, 
the low prevalence of triptan use limited our ability to examine effects of specific 
triptans, as well as producing imprecise estimates of effect. While it is reassuring 
that few women require triptan therapy during pregnancy, replication of these 
findings in populations with higher rates of medication use is necessary to 
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determine whether specific triptans may pose greater risks to fetal development.  
Finally, although several triptans are available in different formulations (e.g., 
tablet vs. nasal spray), no information was available on dose or formulation, 
which precluded more subtle investigations into effects of dose on outcome. Our 
results should be interpreted cautiously, with these strengths and limitations in 
mind. 
 
Conclusion 
Prenatal exposure to triptan medications was associated with a modestly 
increased risk of externalizing behaviors, with the most pronounced risk 
associated with exposure in the first trimester. Because we are unable to rule out 
confounding by indication as an explanation for the observed effects, changes to 
prescribing practices are unwarranted at this time: caution is already 
recommended in the use of triptan in pregnant women, and the evidence of 
possible harm is not sufficient to deprive women of appropriate pharmacotherapy 
during pregnancy. Future studies should include information on migraine type 
and severity as well as medication use to ensure safe and efficacious treatment 
of migraine during pregnancy. 
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Table 2.1.  Maternal characteristics, medication use, and intermediate birth outcomes of 41,173 
included pregnancies 
 History of triptan use No triptan history 
 During 
pregnancy 
Pre-pregnancy 
Only  
Migraine No Migraine 
 N=396 N=798 N=3,291 N=36,688 
Age in years (Mean, SD) 30.8(4.4) 30.5(4.5) 30.3(4.5) 30.4(4.4) 
BMI (kg/m2)     
<18.5  2.81 2.4  3.7  2.6 
18.5-25  59.6  59.9  61.8  66.9 
>25  37.6  37.2  34.5  30.5 
Multiparous   49.2  45.9  53.5  53.4 
Married or cohabitating   95.5  98.0  97.0  97.6 
Mother Education     
Primary or secondary 31.1  31.8  37.0  31.0 
University or higher 68.9  68.2  63.0  69.0 
Smoking during pregnancy 11.4  11.7  13.1  11.1 
Alcohol during pregnancy  20.5  15.0  15.0  17.1 
Folate Supplementation   60.9  62.2  57.8  59.2 
Multivitamin 
Supplementation  
 37.9  43.7  38.9  37.0 
Migraine Preventive 
Therapy 
1.8  1.8  0.6 0.0 
Opioids     
Pre-pregnancy  8.1  5.3 5.1 1.3 
In pregnancy  12.9  4.6 4.9 1.4 
Acetaminophen     
Pre-pregnancy 46.5  47.9 44.8 25.4 
In pregnancy 76.8  70.1 63.7 42.6 
NSAIDs     
Pre-pregnancy 22.0  25.9 23.3 9.9 
In pregnancy 22.5  11.2 12.6 5.9 
Anti-convulsants     
Pre-pregnancy 0.5 0.5 0.2 0.1 
In pregnancy 0.3 0.3 0.3 0.2 
Antidepressants     
Pre-pregnancy 5.3 4.6 3.8 2.2 
In pregnancy 2.0 1.1 1.6 0.9 
Benzodiazepines     
Pre-pregnancy 1.8 1.4 0.9 0.5 
In pregnancy 1.8 0.5 0.5 0.4 
Maternal 
depressive/anxiety 
symptoms1 (Mean, SD) 
0.2(1.7) 0.0(1.8) 0.2(1.9) -0.2(1.6) 
Pre-eclampsia 7.8 4.3 4.0 3.5 
Small for Gestational Age 6.6 6.3 6.5 6.2 
Apgar 5 (<7) 1.5 1.0 0.7 0.9 
Preterm 4.0 4.6 4.8 4.6 
Low Birth Weight  2.0 2.3 2.6 2.4 
1. Figures shown are percent of column total with the exception of maternal age and depressive/anxiety symptom severity, presented as 
mean(standard deviation) 
 
 
   
 37 
Table 2.2.  Specific triptan medications used before and during pregnancy 
 Pre-pregnancy First Trimester Second/third 
Trimester 
Pregnancy Use 
(TU)2 
 N=1,131 N=304 N=137 N=46 
Sumitriptan 44.31 47.2 50.4 47.8 
Rizatriptan  25.8 23.4 27.8 23.9 
Zolmitriptan 17.3  16.8 13.9 26.1 
Eletriptan 11.8 11.2 6.6 4.3 
Naratriptan  2.5  3.3 5.8 2.2 
Almotriptan  2.6 2.6 1.5 6.5 
1.Column percentages sum to greater than 100% due to use of multiple triptans during the study period.  Number of triptan users diverge from those shown on 
Table 1: of 1131 pre-pregnancy users, 798 used only prior to pregnancy and 333 used both before and during pregnancy.   
2. “Pregnancy Use TU” refers to women who used a triptan in pregnancy but did not provide enough information to determine timing; these women were included 
in the main group analyses and excluded from timing models. 
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Table 2.3.  Comparison of risk of clinically-significant externalizing behavior problems for exposure to triptans  
Among all mothers (n=41,173) 
 
 
 
Total N N with 
outcome 
Crude Risk Ratio 
 (95% Confidence  
Interval) 
Adjusted Risk Ratio1 
 (95% Confidence 
Interval) 
Crude Risk 
Difference  
(95% Confidence 
Interval) 
Adjusted Risk 
Difference1  
(95% Confidence 
 Interval) 
Triptans in pregnancy 
 
 
396 46 1.40 
(0.98 to 2.00) 
1.36 
(0.96 to 1.94) 
0.03 
(0.00 to 0.07) 
0.02 
(-0.01 to 0.06) 
 Vs.Triptans pre-
pregnancy only 
798 66 Referent Referent Referent Referent 
       
Triptans in pregnancy 
 
 
396 46 1.32 
(0.98 to 1.77) 
1.33 
(1.00 to 1.78) 
0.03 
(0.00 to 0.06) 
0.02 
(-0.01 to 0.05) 
 Vs. Migraine with no 
triptan use 
3,291 289 Referent Referent Referent Referent 
       
Triptans in pregnancy 
 
 
396 46 1.50 
(1.14 to 1.98) 
1.36 
(1.04 to 1.79) 
0.04 
(0.01 to 0.07) 
0.02 
(-0.01 to 0.05) 
Vs. Population (no 
triptan use or migraine) 
36,688 2,828 Referent Referent  Referent Referent  
1. Models adjusted for maternal age, pre-pregnancy BMI, parity, marital status, education, cigarette and alcohol use, comedication use (NSAIDs, acetaminophen, opioids, antidepressants), depressive and anxiety symptoms.   
2. Marginal structural models weighted with stabilized inverse probability of treatment weights, constructed at each time point using baseline confounders, time-invariant confounders, and medication history. 
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Table 2.3 (Continued) 
Among mothers with migraine (n=4,439) 
 
 
 
Total N N with 
outcome 
Crude Risk Ratio 
 (95% Confidence  
Interval) 
Marginal Structural 
Model Risk Ratio2 
 (95% Confidence 
Interval) 
Crude Risk 
Difference  
(95% Confidence 
Interval) 
Marginal Structural 
Model Risk 
Difference2  
(95% Confidence 
 Interval) 
Pre- pregnancy triptan 
use 
 
1,085 101 0.94 
(0.73 to 1.20) 
0.99 
(0.77 to 1.27) 
-0.02 
(-0.05 to 0.01) 
-0.02 
(-0.05 to 0.00) 
 Vs. No pre-pregnancy 
use  
3,354 297 Referent Referent  Referent Referent  
       
Triptans in 1st trimester 
 
 
304 40 1.77 
(1.23 to 2.56) 
1.75 
(0.98 to 3.14) 
0.06 
(0.01 to 0.10) 
0.06 
(-0.02 to 0.15) 
 Vs. No triptan use in 1st 
trimester 
4,135 358 Referent Referent  Referent Referent  
       
Triptans in 2nd /3rd 
trimester 
 
137 11 0.64 
(0.34 to 1.19) 
0.59 
(0.23 to 1.51) 
-0.02 
(-0.07 to 0.02) 
-0.02 
(-0.11 to 0.07) 
Vs. No triptan use in 
2nd/3rd  trimester  
4,302 387 Referent Referent  Referent Referent  
1. Models adjusted for maternal age, pre-pregnancy BMI, parity, marital status, education, cigarette and alcohol use, comedication use (NSAIDs, acetaminophen, opioids, antidepressants), depressive and anxiety symptoms.   
2. Marginal structural models weighted with stabilized inverse probability of treatment weights, constructed at each time point using baseline confounders, time-invariant confounders, and medication history. 
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Table 2.4.  Comparison of risk of clinically-significant internalizing behavior problems for exposure to triptans  
Among all mothers (n=41,173) 
 
 
 
Total N N with 
outcome 
Crude Risk Ratio 
 (95% Confidence  
Interval) 
Adjusted Risk Ratio1 
 (95% Confidence 
Interval) 
Crude Risk 
Difference  
(95% Confidence 
Interval) 
Adjusted Risk 
Difference1  
(95% Confidence 
 Interval) 
Triptans in pregnancy 
 
 
396 27 0.79 
(0.51 to 1.21) 
0.78 
(0.51 to 1.19) 
-0.02 
(-0.05 to 0.01) 
-0.02 
(-0.05 to 0.01) 
 Vs.Triptans pre-
pregnancy only 
798 69 Referent Referent  Referent Referent  
       
Triptans in pregnancy 
 
 
396 27 0.88 
(0.60 to 1.29) 
0.89 
(0.61 to 1.30) 
-0.01 
(-0.04 to 0.02) 
-0.01 
(-0.03 to 0.01) 
 Vs. Migraine with no 
triptan use 
3,291 255 Referent Referent  Referent Referent  
       
Triptans in pregnancy 
 
 
396 27 1.09 
(0.78 to 1.58) 
1.02 
(0.71 to 1.47) 
0.01 
(-0.02 to 0.03) 
0.00 
(-0.03 to 0.02) 
Vs. Population (no 
triptan use or migraine) 
36,688 2284 Referent Referent  Referent Referent  
1. Models adjusted for maternal age, pre-pregnancy BMI, parity, marital status, education, cigarette and alcohol use, comedication use (NSAIDs, acetaminophen, opioids, antidepressants), depressive and anxiety symptoms.   
2. Marginal structural models weighted with stabilized inverse probability of treatment weights, constructed at each time point using baseline confounders, time-invariant confounders, and medication history. 
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Table 2.4. (continued) 
Among mothers with migraine (n=4,439) 
 
 
 
Total N N with 
outcome 
Crude Risk Ratio 
 (95% Confidence  
Interval) 
Marginal Structural 
Model Risk Ratio2 
 (95% Confidence 
Interval) 
Crude Risk 
Difference  
(95% Confidence 
Interval) 
Marginal Structural 
Model Risk 
Difference2  
(95% Confidence 
 Interval) 
Pre- pregnancy triptan 
use 
 
1,085 86 1.32 
(1.04 to 1.66) 
1.04 
(0.80 to 1.35) 
0.02 
(0.00 to 0.04 
0.00 
(-0.02 to 0.03) 
 Vs.no pre-pregnancy  3,354 260 Referent Referent  Referent Referent  
       
Triptans in 1st trimester 
 
 
304 20 0.90 
(0.54 to 1.48) 
1.27 
(0.57 to 2.82) 
-0.01 
(-0.04 to 0.03) 
0.02 
(-0.06 to 0.10) 
 Vs. No triptan use in 1st 
trimester 
4,135 326 Referent Referent  Referent Referent  
       
Triptans in 2nd /3rd 
trimester 
 
137 7 0.69 
(0.32 to 1.50) 
0.70 
(0.16 to 3.14) 
-0.02 
(-0.07 to 0.02) 
-0.02 
(-0.11 to 0.07) 
Vs. No triptan use in 
2nd/3rd  trimester  
4,302 339 Referent Referent  Referent Referent  
1. Models adjusted for maternal age, pre-pregnancy BMI, parity, marital status, education, cigarette and alcohol use, comedication use (NSAIDs, acetaminophen, opioids, antidepressants), depressive and anxiety symptoms.   
2. Marginal structural models weighted with stabilized inverse probability of treatment weights, constructed at each time point using baseline confounders, time-invariant confounders, and medication history. 
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Figure 2.1.  Inclusion and exclusion of study participants 
 
 
 
   
 
4
3
 
Figure 2.2.  Possible causal model for effect of exposure to triptans on neurodevelopmental outcome 
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Figure 2.3.  Percent of children with clinically-significant behavioral problems in each exposure group 
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Figure 2.4. Time-varying patterns of medication use 
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Table 2.S1. Comparison of unadjusted, multivariable adjusted, and marginal structural model estimates of the effect of timing of triptan 
exposure on behavioral problems (n=4,439) 
 Pre-pregnancy 
use 
No pre-
pregnancy 
use 
1st trimester use No use in 1st 
trimester 
2nd or 3rd 
trimester 
use 
No use in 
2nd or 3rd 
trimester 
   Externalizing 
Problems 
   
N 1,085 3,354 304 4,135 137 4,302 
Number of events 101 297 40 358 11 387 
Risk  9.3% 8.9% 13.2% 8.7% 8.0% 9.0% 
   Risk Ratios    
Unadjusted 
(95% Confidence Interval) 
0.94 
(0.73 to 1.20) 
Referent 1.77 
(1.23 to 2.56) 
Referent 0.64 
(0.34 to 
1.19) 
Referent 
Multivariable adjusted1 
(95% Confidence Interval) 
0.99 
(0.78 to 1.27) 
Referent 1.78 
(1.24 to 2.56) 
Referent 0.63 
(0.34 to 
1.15) 
Referent 
Marginal Structural Model2 
(95% Confidence Interval) 
0.99 
(0.77 to 1.27) 
Referent 1.75 
(0.98 to 3.14) 
Referent 0.59 
(0.23 to 
1.51) 
Referent 
   Risk Differences    
Unadjusted 
(95% Confidence Interval) 
0.00 
(-0.01 to 0.02) 
Referent 0.06 
(0.01 to 0.10) 
Referent -0.03 
(-0.09 to 
0.02) 
Referent 
Multivariable adjusted1 
(95% Confidence Interval) 
0.00 
(-0.02 to 0.02) 
Referent 0.05 
(0.00 to 0.09) 
Referent -0.02 
(-0.08 to 
0.04) 
Referent 
Marginal Structural Model2 
(95% Confidence Interval) 
0.00 
(-0.02 to 0.02) 
Referent 0.06 
(-0.02 to 0.15) 
Referent -0.04 
(-0.09 to 
0.01) 
Referent 
1. Models adjusted for maternal age, pre-pregnancy BMI, parity, marital status, education, cigarette and alcohol use, comedication use (NSA Ds, acetaminophen, opioids, antidepressants), depressive and anxiety 
symptoms. 
2. Marginal structural models weighted with stabilized inverse probability of treatment weights, constructed at each time point using baseline confounders, time-invariant confounders, and medication history. 
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Table 2.S1. (Continued) 
 Pre-pregnancy use No pre-
pregnancy 
use 
1st trimester use No use in 1st 
trimester 
2nd or 3rd 
trimester 
use 
No use in 
2nd or 3rd 
trimester 
   Internalizing 
Problems 
   
N 1,085 3,354 304 4,135 137 4,302 
Number of events 86 260 20 326 7 339 
Risk  7.9% 7.8% 6.6% 7.8% 5.1% 7.9% 
   Risk Ratios    
Unadjusted 
(95% Confidence Interval) 
1.32 
(1.04 to 1.66) 
Referent 0.90 
(0.54 to 1.48) 
Referent 0.69 
(0.32 to 
1.50) 
Referent 
Multivariable adjusted1 
(95% Confidence Interval) 
1.27 
(1.01 to 1.59) 
Referent 0.89 
(0.54 to 1.46) 
Referent 0.69 
(0.32 to 
1.49) 
Referent 
Marginal Structural Model2 
(95% Confidence Interval) 
1.04 
(0.80 to 1.35) 
Referent 1.27 
(0.57 to 2.82) 
Referent 0.70 
(0.16 to 
3.14) 
Referent 
   Risk Differences    
Unadjusted 
(95% Confidence Interval) 
0.02 
(0.00 to 0.04) 
Referent -0.01 
(-0.04 to 0.03) 
Referent -0.02 
(-0.07 to 
0.02) 
Referent 
Multivariable adjusted1 
(95% Confidence Interval) 
0.00 
(-0.01 to 0.02) 
Referent 0.00 
(-0.04 to 0.03) 
Referent -0.03 
(-0.06 to 
0.01) 
Referent 
Marginal Structural Model2 
(95% Confidence Interval) 
0.00 
(-0.02 to 0.03) 
Referent 0.02 
(-0.06 to 0.10) 
Referent -0.02 
(-0.11 to 
0.07) 
Referent 
1. Models adjusted for maternal age, pre-pregnancy BMI, parity, marital status, education, cigarette and alcohol use, comedication use (NSA Ds, acetaminophen, opioids, antidepressants), depressive and anxiety 
symptoms. 
2. Marginal structural models weighted with stabilized inverse probability of treatment weights, constructed at each time point using baseline confounders, time-invariant confounders, and medication history. 
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Table 2.S2.  Additional group-wise comparisons for the risk of externalizing behaviors in disease comparison groups  
Externalizing Symptoms 
 
 
 
Total N N with 
outcome 
Crude Risk Ratio 
 (95% Confidence  
Interval) 
 
Adjusted Risk Ratio1 
 (95% Confidence 
Interval) 
Crude Risk 
Difference  
(95% Confidence 
Interval) 
Adjusted Risk 
Difference1  
(95% Confidence 
 Interval) 
 
Triptans pre-pregnancy 
only 
 
798 66 0.94 
(0.73 to 1.22) 
0.98 
(0.78 to 1.26) 
-0.01 
(-0.03 to 0.02) 
0.00 
(-0.02 to 0.02) 
 Vs. Migraine with no 
triptan use 
3,291 289 Referent Referent  Referent Referent  
       
Triptans pre-pregnancy 
only 
 
798 66 1.07 
(0.85 to 1.36) 
1.00 
(0.79 to 1.26) 
0.01 
(-0.01 to 0.02) 
0.00 
(-0.02 to 0.02) 
 Vs. Population (no 
triptan use or migraine) 
36,688 2,828 Referent Referent  Referent Referent  
       
Migraine with no triptan 
use 
 
3,291 289 1.14 
(1.01 to 1.28) 
1.02 
(0.92 to 1.15) 
0.01 
(0.00 to 0.02) 
0.00 
(-0.01 to 0.01) 
Vs. Population (no 
triptan use or migraine) 
36,688 2,828 Referent Referent  Referent Referent  
1. Models adjusted for maternal age, pre-pregnancy BMI, parity, marital status, education, cigarette and alcohol use, comedication use (NSAIDs, acetaminophen, opioids, antidepressants), depressive and anxiety symptoms.   
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Table 2.S2.  (Continued) 
Internalizing Symptoms 
 
 
 
Total N N with 
outcome 
Crude Risk Ratio 
 (95% Confidence  
Interval) 
 
Adjusted Risk Ratio1 
 (95% Confidence 
Interval) 
Crude Risk 
Difference  
(95% Confidence 
Interval) 
Adjusted Risk 
Difference1  
(95% Confidence 
 Interval) 
 
Triptans pre-pregnancy 
only 
 
798 69 1.12 
(0.87 to 1.45) 
1.15 
(0.89 to 1.47) 
0.01 
(-0.01 to 0.03) 
0.01 
(-0.01 to 0.03) 
 Vs. Migraine with no 
triptan use 
3,291 255 Referent Referent Referent Referent 
       
Triptans pre-pregnancy 
only 
 
798 69 1.39 
(1.10 to 1.75) 
1.31 
(1.04 to 1.65) 
0.02 
(0.00 to 0.04) 
0.02 
(0.00 to 0.04) 
 Vs. Population (no 
triptan use or migraine) 
36,688 2284 Referent Referent Referent Referent 
       
Migraine with no triptan 
use 
 
3,291 255 1.24 
(1.10 to 1.41) 
1.14 
(1.01 to 1.30) 
0.02 
(0.01 to 0.02) 
0.01 
(0.00 to 0.02) 
Vs. Population (no 
triptan use or migraine) 
36,688 2284 Referent Referent Referent Referent 
1. Models adjusted for maternal age, pre-pregnancy BMI, parity, marital status, education, cigarette and alcohol use, comedication use (NSAIDs, acetaminophen, opioids, antidepressants), depressive and anxiety symptoms.   
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Table 2.S3. Bias analysis for the potential impact of confounding by migraine severity on the observed effect estimates for externalizing 
behavior problems 
 Association between 
migraine severity and 
outcome  
(RRCD) 
Prevalence of severe 
migraine in triptan users  
 
(p1) 
Prevalence of severe migraine 
in triptan discontinuers  
 
(p0) 
Risk 
Ratio1 
95% 
Confidence 
Interval 
Conventional 
Result 
-- -- -- 1.40 0.98 to 2.00 
      
      
Scenario 1 1.25 0.30 0.15 1.36 0.94 to 1.95 
      
Scenario 2 1.25 0.40 0.20 1.34 0.98 to 2.17 
      
Scenario 3 1.5 0.30 0.15 1.31 0.93 to 1.86 
      
Scenario 4 1.5 0.40 0.20 1.29 0.91 to 1.83 
      
Scenario 5 3.00 0.40 0.20 1.09 0.77 to 1.56 
      
Scenario 6 4.00 0.40 0.20 1.03 0.71 to 1.52 
1. Bias-corrected RR based on 10,000 simulations from a uniform distribution 
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CHAPTER III 
 
PRENATAL TRIPTAN EXPOSURE AND EARLY CHILDHOOD 
NEURODEVELOPMENTAL OUTCOMES: AN APPLICATION OF PROPENSITY 
SCORE CALIBRATION TO ADJUST FOR UNMEASURED CONFOUNDING BY 
MIGRAINE SEVERITY 
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III.0     Abstract  
 
Background: Triptan medications are serotonin agonists used to treat migraine, a 
chronic pain condition highly prevalent in women of reproductive age. Data on 
the safety of triptans during pregnancy are scant. We sought to quantify the 
association of prenatal triptan exposure on motor function, communication skills, 
and temperament in three-year-old children. 
Methods: Using data from the Norwegian Mother and Child Cohort Study, we 
used propensity score matching to examine associations between prenatal 
triptan exposure and psychomotor function, communication, and temperament. 
We used an external validation study to perform propensity calibration to adjust 
effect estimates for confounders unmeasured in the main study (migraine 
severity, type, and maternal attitudes towards medication use). 
Results: We identified 4,204 women who reported migraine headache at 
baseline, of which 375 (8.9%) reported using a triptan ≥ once during pregnancy. 
Children with prenatal triptan exposure had 1.37-fold greater unadjusted odds of 
fine motor problems (95% CI: 1.06-1.77), which decreased after propensity score 
matching (OR: 1.29, 95% CI 0.97-1.73) and was further attenuated after 
calibration (OR: 1.25, 95%CI 0.89- 1.74). We observed no increased risk for 
gross motor or communication problems, and no differences in temperament. 
Adjustment for migraine severity using propensity score calibration had a 
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substantial impact on effect estimates, with percent changes ranging from 2.4% 
to 50%. 
Conclusions: Prenatal triptan exposure was not associated with psychomotor 
function, communication problems, or temperament in three-year-old children. 
Adjustment for migraine severity reduced effect estimates, and should be 
considered in future studies of the safety of triptans during pregnancy. 
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III.1     Introduction 
Migraine headache is a relapsing-remitting chronic pain condition with a 
one year prevalence in women of reproductive age of 16-18%.5,6 The frequency 
and severity of migraines often changes over the course of pregnancy: 60-70% 
of women with migraine experience some improvement of symptoms during 
pregnancy, with 20% of these reporting complete remission. Migraine course 
during pregnancy tends to be better in women with menstrual migraine as well as 
in women who have migraines without aura.6 However, if symptoms do not 
improve during the first trimester, migraines are likely to continue throughout 
pregnancy.6 Given the high prevalence of migraine headache in women of 
childbearing age, the lack of migraine resolution until after the first trimester, and 
the high rate of unplanned pregnancy,4 the potential for early-pregnancy 
exposure to medications used to treat migraines is high. 
Pharmacotherapy for migraine includes both preventive and analgesic 
medications, and triptans are the most frequently-used prescription medications.9 
Triptans are serotonin 5-HT1B, 5-HT1D and 5-HT1F receptor agonists that act on 
the trigeminal cervical complex as well as on smooth muscle; they are taken 
episodically, as a migraineur feels a migraine attack beginning. There are seven 
triptans commercially available worldwide: sumatriptan, zolmitriptan, naratriptan, 
rizatriptan, almotriptan, eletriptan and frovatriptan. 
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Ten studies (including more than 6,000 exposed infants) have examined the 
safety of triptan use during pregnancy on immediate pregnancy outcomes, and 
have noted no increased risk for major congenital malformations,12,37,76 although 
some evidence suggests that triptan use may be associated with pre-eclampsia 
or preterm birth.12 In light of the current literature, a recent review of treatment 
options for pregnant women with migraine, concluded that if acetaminophen was 
not sufficiently effective, limited use of triptans could be considered during 
pregnancy, with a preference for sumatriptan.15 
While several studies focus on the immediate pregnancy outcome 
following exposure to triptans, the long-term outcomes have received surprisingly 
limited attention. Triptans readily cross the placenta and the blood-brain barrier 
and may bind to 5-HT1B and 5-HT1D receptors which are found in fetal brain,18 
and have therefore a biological plausible mechanism for effects on the 
developing brain.  Previously, we evaluated prenatal triptan exposure as a risk 
factor for internalizing and externalizing behaviors, and found that children 
exposed prenatally to triptans had a 40% increased risk for clinically-significant 
externalizing problems; we did not observe an increased risk for internalizing 
problems.77 This was the first study on long-term safety of triptans; however, it is 
unknown whether prenatal exposure to triptans or migraine in itself may increase 
the risk of other neurodevelopmental outcomes like psychomotor development, 
temperament and communication.  
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Building from our previous work, the current study sought to evaluate the 
effect of in utero exposure to triptans on psychomotor problems and 
temperamental disturbances. We hypothesized that children born to women who 
took a triptan medication during pregnancy would have higher rates of 
psychomotor problems and temperamental disturbances than children 
unexposed to triptans; we further hypothesized that if these problems were due 
to the underlying disorder, adjustment for migraine severity would be necessary. 
Understanding the role of triptans as possible teratogens requires careful 
consideration of the role of the underlying disease. 
 
III.2     Methods 
Norwegian Mother and Child Cohort Study (MoBa) Sample  
Between 1999 and 2008, the Norwegian Institute of Public Health invited 
women to participate in the Norwegian Mother and Child Cohort Study (MoBa). 
Women were invited prior to their first routine ultrasound appointment 
(gestational week 13-17). A total of 108,841 women consented to participate 
(participation rate 42.7%), with 84.8% of the participants completing the six 
month post-partum questionnaire and 60.2% completing the 36 month post-
partum questionnaire.46,78 Written informed consent was obtained from all 
participants, and the Regional Committee for Medical Research Ethics and the 
Norwegian Data Inspectorate approved the study; this analysis was granted an 
exemption from the University of Massachusetts Medical School Institutional 
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Review Board. Data were taken from the quality-ensured Data Version 6, 
released by MoBa in 2012 and includes all children born before 2009 for whom 
the age three years questionnaire was received by May 4, 2011; these data were 
linked to the Medical Birth Registry of Norway (MBRN) using participants’ 11-digit 
personal identification numbers. Figure 3.1 shows the exclusion criteria and the 
development of the analysis sample (n=4,204).  
Ascertainment of triptan exposure 
Information on exposure to medications was gathered prospectively from 
two prenatal (Q1-gestational week17, Q3-gestational week 30) and one 
postpartum questionnaire (Q4-6 months post partum).  Women were asked to 
indicate when they had taken a medication (during the six months before 
pregnancy, during weeks 0-4, 5-8, 9-12, and/or 13 or later for Q1, during weeks 
13-16, 17-20, 21-24, 25-28, and/or week 29 or later for Q3, and from week 30 
until birth for Q4), and to write the name of the medication in a text box.  Women 
who indicated multiple medications in a single text box (e.g., sumitriptan and 
acetaminophen) were assumed to have been exposed to all listed medications in 
all time periods.  No information was available on formulation or dose.  Exposure 
was categorized into two indicator variables: triptan use during pregnancy (yes or 
no) and triptan use prior to pregnancy (yes or no).  
Ascertainment of outcome 
   
 59 
To build on previous work examining the effect of prenatal triptan exposure on 
internalizing and externalizing symptoms, we chose two domains of 
neurodevelopment: temperament and psychomotor function. 
Emotionality, Activity, and Shyness Temperament Questionnaire (EAS)  
The Emotionality, Activity, and Shyness Temperament Questionnaire 
measures four temperament domains (emotionality, shyness, sociability, and 
activity). A substantial body of literature has linked early childhood temperament 
to later life depression and other psychiatric diagnoses.79,80 The shortened 
version of the EAS used in the MoBa study, was developed with Norwegian 
social norms in mind, and includes 12 descriptions (e.g. “Your child likes to be 
with people;” “Your child cries easily.”), and parents are asked to rate how well 
each statement applies to their child; in a Norwegian sample, the four factor 
structure of the original scale was reproduced, and internal consistency within 
each scale ranged from α=0.48 to α=0.79. 81 We calculated z-scores based on 
the sample distribution of each domain. Higher z-scores indicate greater parental 
endorsement of each temperament trait (e.g. more shy, or more sociable) relative 
to parental reports of other children in the sample.  
Ages and Stages Questionnaire (ASQ) 
The Ages and Stages Questionnaire is a parent-completed questionnaire 
appropriate for children aged four months to five years. Deficits detected by the 
ASQ have been shown to be predictive of school difficulties in older children,82 
and fine motor skills are highly predictive of later academic achievement.83 The 
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abbreviated ASQ used in MoBa includes questions about developmental 
milestone attainment in three major categories: gross motor, fine motor, and 
communication; this shortened version has been validated in a Norwegian 
population, and had excellent test-retest reliability (94%) and agreement between 
parents and professional examiners, as well as acceptable sensitivity and 
specificity (72% and 86%, respectively)84. We categorized each domain of the 
ASQ to indicate whether a child had a delay in at least one motor skill or at least 
two communication skills assessed, identified by a parent reporting “Not yet” 
(versus “Yes” or “Sometimes”). 
Concomitant medication use 
We examined other pain medications and psychotropic medications as 
potential confounders, using the following ATC codes: N02BE01 
(acetaminophen), N02A (opioids), M01A (non-steroidal anti-inflammatory drugs, 
NSAIDs), N06A (antidepressants), N05CD02, N05CD03, N05CD08, N05BA01, 
N05BA05, N05BA12 (benzodiazepines), and N03A (anti-convulsants). All co-
medications were categorized as ever vs. never used in pregnancy and prior to 
pregnancy.  
Potential confounders 
Maternal age, pre-pregnancy body mass index (BMI) (underweight or 
<18.5 kg/m2, normal weight or 18.5-25 kg/m2, or overweight, >25 kg/m2 
according to WHO guidelines), education (primary or secondary vs university or 
higher), marital status (married or cohabiting vs other), parity (multiparous vs. 
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primiparous) and depression history (yes or no) were all ascertained by self-
report on Q1. Smoking (ever during pregnancy vs. not during pregnancy) and 
alcohol use (ever during pregnancy vs. not during pregnancy) were ascertained 
by combining information from self-report and linkage to the Medical Birth 
Registry of Norway. 
MIMEGA Migraine sample description  
Women with migraine who were ≥ 18 years of age and who were currently 
pregnant or had a child <18 months old were invited to participate in the 
MIMEGA migraine study85 from October 2013-January 2014. Recruitment was 
done by the Oslo Migraine Clinic and the Norwegian Migraine Association, in 
addition to advertisements on websites for pregnant women and new mothers 
and on the study’s Facebook page. Women filled out an anonymous electronic 
questionnaire developed using the Online Forms Service of the University of 
Oslo (http://www.nettskjema.uio.no/). The Regional Committee for Medical and 
Health Research Ethics (Region North) approved the study, and informed 
consent was obtained (n=380).  The MIMEGA study includes important 
information on migraine type, severity, and beliefs about medication use, which 
were not assessed in the main MoBa study. 
Women self-reported their age, gestational week (if pregnant) or age of 
child (if post-partum), education (primary or secondary vs university or higher), 
marital status (married or cohabiting vs other), parity (multiparous vs. 
primiparous) smoking and alcohol use during pregnancy (any use after learning 
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she was pregnant vs. no use), and use of other medications (including triptans, 
acetaminophen, NSAIDs, and opioids). 
Women were asked about the severity of migraine attacks during 
pregnancy using the Migraine Severity Scale 86, a four item questionnaire that 
assessed pain severity, tolerance, nausea, and impairment of daily activity due to 
migraine. Scores range from 0 to 15, and higher scores indicate more severe 
migraine. The Beliefs About Medications Questionnaire (BMQ) 87,88 includes 10 
statements designed to assess patients’ concerns about medications and their 
views on medication necessity.  The BMQ includes two subscales: the BMQ-
Necessity and the BMQ-Concerns, each with five items; respondents indicate 
their agreement with each item (1=strongly disagree, 5=strongly agree), and 
individual items are summed to produce a total score which ranges from 5-25, 
with higher scores indicating greater belief in the concepts represented by the 
subscale (concerns about medications or greater perceived need of medications, 
respectively).  
Statistical Analysis 
We began analysis by estimating the prevalence of triptan exposure 
during pregnancy, and then obtaining descriptive statistics for the sample 
(collectively and by prenatal triptan exposure). Four modeling approaches were 
used to provide: 1) multivariable adjusted estimates; 2) propensity score matched 
estimates; 3) propensity score adjusted estimates; and 4) propensity score 
calibration estimates.  
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We modeled the EAS temperament outcomes by fitting general linear 
models and the ASQ delay outcomes by fitting logistic models. Other functional 
forms of the generalized linear model, including Poisson models, were assessed 
and compared using goodness-of-fit metrics and visual inspection of data. For 
both outcomes, we followed the similar model-building strategies. We began with 
an unadjusted model in which triptan use in pregnancy was the only variable. 
Then, we added potential confounders into the model singly to assess the extent 
to which each confounder changed the measure of association between triptan 
use in pregnancy and the outcome variable. The final set of confounders used in 
all models was selected from a combination of literature review, iterative use of 
directed acyclic graphs, and substantial (>10%) change in the measure of 
association for the triptan variable (indicating material confounding), and 
included: maternal age, pre-pregnancy BMI, marital status, maternal education, 
smoking or alcohol use during pregnancy, presence of maternal depression, use 
of triptans prior to pregnancy, and concomitant medication use during pregnancy 
(acetaminophen, NSAIDs, opioids, antidepressants). 
Propensity score methods remove substantial bias in effect estimates that 
arise from measured differences between the exposed and unexposed groups, 
and assuming no unmeasured confounding, allow us to estimate causal effects. 
We used logistic regression in which prenatal triptan exposure was the outcome 
variable and the variables previously selected as material or theoretical 
confounders during multivariable model building were predictors. Our propensity 
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score model had a c-statistic of 0.86, and visual inspection of the propensity 
score distribution showed substantial overlap between the exposed and 
unexposed women. We implemented propensity score matching without 
replacement using psmatch_multi, a SAS macro that uses local matching to 
retain matches for the exposed units with the least number of possible matches 
first; we performed a 1:2 match, selecting two unexposed women for every 
exposed individual, with non-replacement and a caliper of 0.10.  To asses 
whether matching on the propensity score had produced comparable groups, we 
used logistic regression to determine whether the measured confounders in our 
study predicted triptan exposure in the matched sample; the c-statistic was 0.57, 
suggesting that the matched cohort was relatively balanced with respect to 
measured confounders. We also compared the characteristics of the exposed 
and unexposed women in the matched sample. We then compared the 
neurodevelopmental outcome measures (EAS and ASQ subscales) using 
general linear models for the continuous EAS outcomes and logistic regression 
for the categorical ASQ outcomes. These analyses included covariates that 
remained unbalanced after propensity matching.   
We estimated an effect from the full sample with propensity score included 
as a covariate. Although adjustment for propensity score is not the optimal use of 
propensity score methods, adjustment for propensity score yields more stable 
estimates than multivariable adjustment, in the case of a rare exposure and a 
complex model with many predictors; in addition, these estimates were 
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compared with propensity-calibrated estimates to better understand the potential 
impact of unmeasured confounders.  
   
Stabilized Inverse Probability of Censoring Weights 
 To address differential loss to follow up by triptan use (Figure 3.1), we 
identified factors associated with attrition, and created stabilized inverse 
probability of censoring weights (IPCW) using logistic regression.62 The 
censoring weight included maternal age, pre-pregnancy BMI, marital status, 
education, reproductive history, depression, concomitant medication use, and 
use of triptans prior to and during pregnancy. This method ensures balance of 
measured predictors of attrition, which reduces selection bias.  
Propensity score calibration 
The MoBa study did not include information on several potentially 
important confounders for this study question, including migraine type, migraine 
severity, concerns about medications, and belief in the necessity of medications. 
To adjust for these unmeasured confounders, we implemented a method first 
described by Sturmer et al 89, which combines propensity score adjustment with 
regression calibration using an external validation study. To implement 
propensity score calibration, we first estimated an “error-prone” propensity score 
in the MIMEGA sample using only the confounders available in both the MoBa 
sample and the MIMEGA sample: age, education, marital status, parity, smoking 
or alcohol use during pregnancy, history of depression, use of triptans prior to 
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pregnancy, and concomitant medication use during pregnancy (opioids, 
acetaminophen, NSAIDs).  Next, we estimated a “gold standard” propensity 
score in the MIMEGA study using predictors available in MoBa and predictors 
unmeasured in Moba but available in our external validation sample, including 
migraine type, severity, and medication attitudes. The c-statistics for the error-
prone propensity score model and gold-standard propensity score model were 
0.81 and 0.87, respectively, indicating that the addition of information from the 
new predictors improved the gold-standard PS. Because regression calibration 
may fail in the presence of extreme measurement error (in this case, if the error-
prone PS and gold standard PS widely diverged), we estimated the correlation 
between the two propensity scores and found it to be acceptable (r=0.81-0.89). 
Finally, we used a freely available SAS macro (available at 
http://www.hsph.harvard.edu/donna-spiegelman/software/blinplus-macro/) to 
calibrate the error-prone PS estimated in MoBa using regression parameters 
obtained in the external validation study, and calculated the percent change 
(calculated as [ (PSCadjusted – PSadjusted) / PSCadjusted ] *100) from the PS-adjusted 
models to the PS-adjusted and calibrated models, to understand the magnitude 
of the impact that confounding by migraine type, severity, and medication 
attitudes may have had on our effect estimates. 
 
III.3     Results 
MoBa Sample Description 
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Of the 4,204 women included in this study, 25.4% reported use of triptans 
in the six months prior to pregnancy and 8.9% used a triptan at least once during 
pregnancy. Among prenatal triptan users, 77.4% used during the first trimester, 
34.1% during the second and third trimesters, and 11.5% reported triptan use 
during pregnancy but did not report timing of exposure. Women who took a 
triptan during pregnancy more often had a history of triptan use prior to 
pregnancy, and during pregnancy, were more likely to have used opioids, 
acetaminophen, and NSAIDs than those who did not. Women who used triptans 
during pregnancy were more likely to drink alcohol than those who did not. Rates 
of concomitant medication use were higher among women who used triptans 
during pregnancy, while women who did not use triptans prior to pregnancy more 
often discontinued use of other medications. After propensity score matching, 
balance improved between exposed and unexposed groups on pre-pregnancy 
use of medications triptans and opioids, and alcohol using during pregnancy; use 
of opioids and NSAIDs during pregnancy remained somewhat unbalanced after 
matching (Table 3.1). 
MIMEGA Calibration Sample Description 
Among women who participated in the MIMEGA study (n=380), 12.1%, 
reported triptan use during their pregnancy. Triptan users were more likely than 
non-users to report depression, were overwhelmingly more likely to have taken 
triptans prior to pregnancy, and had far higher rates of use of opioids, 
acetaminophen and NSAIDs during pregnancy. Women who reported taking a 
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triptan during pregnancy reported higher migraine severity, were more likely to 
believe migraine medications were necessary, and showed higher levels of 
concern about using migraine medications than women who did not take triptans 
during pregnancy. Prenatal triptan users were also more likely to report having 
migraine without aura and less likely to be unsure about their type of migraine 
than women who did not report triptan use during pregnancy (Table 3.2).  
Comparison of MoBa and MIMEGA samples 
 Comparing the characteristics of the MoBa and MIMEGA samples 
revealed several differences, particularly in education, rates of cigarette and 
alcohol use in pregnancy, rate of folate supplementation, and rate of other 
medication use prior to and during pregnancy (Table 3.2). However, when we 
examined the associations between individual confounders and use of triptans 
during pregnancy for the MoBa and calibration studies, we found that maternal 
age and use of opioids, acetaminophen, and NSAIDs during pregnancy were 
similarly associated with triptan use during pregnancy, as was pre-pregnancy 
triptan use and pre-pregnancy opioid use, albeit with some differences in point 
estimates and wider 95% confidence intervals owing to the differences in sample 
sizes. Migraine severity was associated with triptan use in pregnancy, as were 
beliefs about medication necessity and concerns about medication use; migraine 
type was not associated with triptan use (Table 3.3). 
Main Outcome Analysis 
Ages and Stages Questionnaire 
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 In the MoBa sample, 2.5% of children had a gross motor delay, 18.0% had 
a fine motor delay, and 1.3% had a communication delay. Unadjusted estimates 
for fine motor delays suggested an increased risk associated with prenatal triptan 
exposure (Odds Ratio (OR) 1.37, 95% Confidence Interval (CI): 1.06 to 1.77), 
which was reduced after propensity matching (OR 1.29, 95% CI: 0.94 to 1.76); 
multivariable and propensity adjustment attenuated this risk. No association was 
observed between prenatal triptan exposure and gross motor or communication 
delays (Table 3.4). 
Emotionality, Activity, and Shyness Temperament Questionnaire  
Before adjustment, children exposed to triptans during fetal development 
had slightly higher mean shyness ( 0.08, 95%CI -0.04 to 0.19); adjustment for 
propensity for triptan use, however, moved estimates closer to the null ( 0.05, 
95%CI -0.07 to 0.18).  No association was observed between triptan exposure 
and sociability, emotionality, or activity (Table 3.4). 
Sensitivity Analysis: Propensity score calibration 
 To consider confounding by migraine type, severity, and medication 
attitudes, we performed propensity-score calibrations. In most cases, PS-
calibrations either moved point estimates closer to zero, with percent differences 
ranging from 8.8-50% relative to PS-adjusted models (EAS Sociability, Activity, 
and Shyness Scales; ASQ Fine Motor and Communication delays), suggesting 
that some unmeasured confounding by migraine type, severity, and medication 
attitudes was present in the traditional PS-adjusted effect estimates (Table 3.5). 
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III.4     Discussion 
Within the 10.9% of women in the MoBa study who reported migraine 
headache at baseline, 8.9% used a triptan medication at least once during 
pregnancy, which underscores the need for more information about the safety of 
these medications during pregnancy. The current study found no association 
between prenatal exposure to triptans and motor delays, communication delays, 
or temperament, after adjustment for measured confounders and calibration for 
unmeasured confounders. Fine motor delays were relatively common (18% of 
sample) while gross motor and communication delays were rare (2.5% and 1.3%, 
respectively), which is not unexpected given the age of assessment. Mean 
temperament scores were variable, but covered the range of scores found in the 
larger MoBa study.  
These findings contrast with our previous work, which noted an increased 
risk of externalizing behaviors in children exposed to triptans during fetal 
development.77 One possible explanation for these differences is that 
externalizing behaviors, motor and communication skills, and temperament are 
associated with different brain regions, which may be differentially sensitive to 
teratogens during development: further study is needed to better understand 
these vulnerabilities and their potential neurodevelopmental consequences. 
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There may be other explanations for the lack of observed association between 
prenatal triptan exposure and psychomotor problems or temperament. Because 
triptan use in pregnancy is a relatively rare in the MoBa cohort, we may have 
failed to detect differences between exposed and unexposed groups due to lack 
of power. For continuous outcomes, this study had adequate power to detect 
moderate effects, or effect sizes of d=0.20 or greater. For categorical outcomes, 
however, the study had sufficient power to detect an odds ratio of 1.7 or greater, 
suggesting that for gross motor and communication problems, we may have 
failed to detect more subtle effects. It is also possible that the null result we 
observed could be due to non-differential misclassification of exposure. 
Techniques to adjust for non-differential misclassification using propensity score 
methods are (to our knowledge) unavailable.  
We hypothesized that migraine characteristics, including severity, would 
be associated with a woman’s likelihood of taking a triptan during pregnancy. 
Migraine itself is associated with adverse pregnancy outcomes, including 
hypertensive disorders, preterm birth90,91 and low birth weight,90 and increased 
risk of neurodevelopmental problems in children exposed in utero.68 This study 
provides evidence that migraine severity and medication beliefs were associated 
with triptan use in pregnancy. Independent of medication use, migraine severity 
in particular may also be associated with child neurodevelopment: chronic pain is 
related to increased stress response, which in turn is associated with 
neurodevelopmental problems in children.92 We found that adjusting for migraine 
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severity did influence our observed effect estimates, even within the context of a 
null study. Failing to appropriately consider these facets of the underlying 
indication for which the triptan medication is used could lead to overestimating 
the risk of prenatal triptan exposure. This underlines the need for studies of 
medication use during pregnancy to carefully consider the role of the underlying 
medical condition for which the medication was prescribed in any findings. 
 Our study had several important limitations. The MoBa study did not 
collect information on migraine type or severity, and results from our propensity 
calibration analysis suggest that adjustment for these factors tended to move 
effect estimates towards the null. We used the MIMEGA study to apply 
propensity score calibaration.  The MIMEGA sample was recruited as many as 
10 years after the MoBa sample, and may be different from the MoBa sample in 
multiple ways, including education, severity, or concern about medication safety. 
The propensity score calibration is dependent on an assumption of surrogacy, 
which states that the error-prone propensity score in the main MoBa study is 
independent of the outcome given the gold-standard propensity score in the 
validation study.93 Neurodevelopmental outcomes were not measured in the 
MIMEGA study, and so the surrogacy assumption is not verifiable. However, we 
hypothesized that the direction of confounding was similar for the variables 
measured in the MIMEGA and MoBa studies, and so should not result in a 
violation of surrogacy.94  
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Despite these limitations, this study makes several important 
contributions. First, the study is set in the Norwegian Mother and Child Cohort 
Study, a prospective birth cohort in which information on medication exposure 
was gathered prior to observing any neurodevelopmental outcomes and 
therefore minimizing the potential for differential information bias. We applied 
multiple methodological techniques to minimize, assess, and where possible, 
reduce bias due to measured and unmeasured confounders. Women who took 
triptans during pregnancy were different from those who did not in a variety of 
ways, including the number of concomitant medications taken, history of 
depression, and alcohol use during pregnancy, as well as migraine severity and 
attitudes towards medication use: failure to adequately consider these 
confounders could have led us to attribute teratogenic effects to triptans that 
might be more properly attributed to underlying disease severity.  
Our prior work identified increased risks of externalizing behaviors 
associated with prenatal triptan exposure; the current study, focusing on 
temperament, psychomotor problems, and communication problems revealed no 
differences between children with and without prenatal triptan exposure. Taken 
together, the evidence so far is not sufficient to recommend changes to 
guidelines for use of triptans during pregnancy, which currently suggest that 
these medications may be used conservatively. Future studies should take into 
account migraine severity when considering the possible effects of prenatal 
exposure to triptan medications. 
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Table 3.1. Maternal characteristics and medication use among women with history of migraine 
headache in the Norwegian Mother and Child Cohort Study (MoBa), before and after propensity 
score matching 
 Full Sample Propensity-Matched Sample 
 Triptans In 
Pregnancy 
No Triptans In 
Pregnancy  
Triptans In 
Pregnancy 
No Triptans In 
Pregnancy  
 N=375 N=3,829 N=365 N=730 
Age in years (Mean, 
SD) 
30.9(4.3) 30.3(4.4) 30.8(4.3) 30.8(4.1) 
BMI (kg/m2)     
<18.5  2.71 3.5 2.7 2.6 
18.5-25  60.3 61.6 60.0 62.2 
>25  37.1 34.9 37.3 35.2 
Multiparous   47.7 51.8 48.0 47.5 
Married or cohabitating   95.5 97.2 95.9 97.0 
Mother Education     
Primary or secondary  30.1 35.6 30.4 29.6 
University or higher  69.9 64.4 69.6 70.4 
Smoking during 
pregnancy 
 11.7 12.7 11.8 11.9 
Alcohol during 
pregnancy 
 20.3 15.2 19.5 18.0 
Folate Supplementation   60.8 58.8 60.8 62.1 
Medications Taken In 
Pregnancy 
    
Opioids 12.8 4.8 10.4 6.1 
Acetaminophen 76.0 65.0 75.3 73.6 
NSAIDs  22.4 12.1 20.8 13.2 
Anticonvulsants 0.3 0.3 0.3 0.1 
Antidepressants 1.6 1.5 1.6 1.2 
Benzodiazepines  1.6 0.5 1.4 0.7 
Medications Before 
Pregnancy 
    
Triptans 84.0 19.7 83.6 83.4 
Opioids 7.7 15.1 6.9 6.4 
Acetaminophen 46.1 45.4 45.8 48.1 
NSAIDs  21.9 23.8 20.8 25.5 
Anticonvulsants 0.5 0.3 0.6 0.3 
Antidepressants 5.1 3.9 5.2 4.7 
Benzodiazepines  1.3 1.0 1.6 1.5 
Maternal Depression 12.3 12.2 12.3 12.6 
1. Values reported are column percents; age is reported as mean(standard deviation) 
 
 
 
 
 
 
 
 
 
 
   
 75 
Table 3.2. Maternal characteristics and medication use among women with history of migraine 
headache, full sample and calibration sample 
 MoBa Study MIMEGA Study 
 Triptans In 
Pregnancy 
No Triptans In 
Pregnancy  
Triptans In 
Pregnancy 
No Triptans In 
Pregnancy  
 N=375 N=3,829 N=46 N=334 
Age in years (Mean, SD) 30.9(4.3) 30.3(4.4) 31.5(5.9) 30.7(4.9) 
BMI (kg/m2)     
<18.5 2.7 3.5 -- -- 
18.5-25 60.3 61.6 -- -- 
>25 37.1 34.9 -- -- 
Multiparous  47.7 51.8 69.6 82.6 
Married or cohabitating  95.5 97.2 93.5 95.2 
Mother Education     
Primary or secondary 30.1 35.6 67.4 75.5 
University or higher 69.9 64.4 32.6 24.6 
Smoking during pregnancy 11.7 12.7 8.7 6.6 
Alcohol during pregnancy 20.3 15.2 8.7 1.8 
Folate Supplementation  60.8 58.8 89.1 86.5 
Medications Taken In 
Pregnancy 
    
Opioids 12.8 4.8 23.9 9.3 
Acetaminophen 76.0 65.0 78.3 65.3 
NSAIDs  22.4 12.1 23.9 6.0 
Anticonvulsants 0.3 0.3 -- -- 
Antidepressants 1.6 1.5 -- -- 
Benzodiazepines  1.6 0.5 -- -- 
Medications Before Pregnancy     
Triptans 84.0 19.7 97.8 61.7 
Opioids 7.7 5.1 21.7 18.3 
Acetaminophen 46.1 45.4 73.9 65.0 
NSAIDs  21.9 23.8 60.9 58.1 
Anticonvulsants 0.5 0.3 -- -- 
Antidepressants 5.1 3.9 -- -- 
Benzodiazepines  1.3 1.0 -- -- 
Maternal Depression 12.3 12.2 8.7 4.2 
Migraine Type     
With Aura -- -- 37.0 42.8 
Without Aura -- -- 43.5 31.7 
Other/Do not know -- -- 19.6 25.5 
Migraine Severity Score 
(MIGSEV) (Mean, SD) 
-- -- 12.0(2.6) 9.1(4.7) 
Beliefs About Medicines 
Questionnaire (BMQ): 
Necessity Subscale (Mean, SD) 
-- -- 18.1(4.0) 13.9(5.0) 
Beliefs About Medicines 
Questionnaire (BMQ): Concern 
Subscale (Mean, SD) 
-- -- 15.4(4.2) 13.5(4.5) 
1. Values reported are column percents; age, Migraine Severity Score, and Beliefs About Medicines Questionnaire are 
reported as mean (standard deviation) 
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Table 3.3. Propensity for use of triptans in pregnancy for the main (“MoBa”) study and the 
external validation study (“MIMEGA”) 
 MoBa Study MIMEGA Study 
  
Odds 
Ratio 
95% 
Confidence 
Interval  
 
Odds 
Ratio 
95% 
Confidence 
Interval  
     
Age in years1 1.0 1.0 to 1.1 1.0 1.0 to 1.1 
BMI (kg/m2)     
<18.5 0.8 0.4 to 1.5 -- -- 
18.5-25 REF  -- -- 
>25 1.1 0.9 to 1.4 -- -- 
Multiparous  0.9 0.7 to 1.1 0.5 0.2 to 1.0 
Married or cohabitating  0.6 0.4 to 1.0 0.7 0.2 to 2.6 
Mother Education     
University or higher vs. other categories 0.8 0.6 to 1.0 1.5 0.8 to 2.9 
Smoking during pregnancy 0.9 0.7 to 1.3 1.4 0.4 to 4.1 
Alcohol during pregnancy 1.4 1.1 to 1.9 5.2 1.4 to 19.2 
Folate Supplementation  1.1 0.9 to 1.4 1.3 0.5 to 3.4 
Medications Taken In Pregnancy     
Opioids 2.9 2.1 to 4.1 3.1 1.4 to 6.6 
Acetaminophen 1.7 1.3 to 2.2 1.9 0.9 to 4.0 
NSAIDs  2.1 1.6 to 2.7 4.9 2.2 to 11.1 
Anticonvulsants 0.9 0.1 to 6.6 -- -- 
Antidepressants 1.1 0.5 to 2.6 -- -- 
Benzodiazepines  2.6 1.0 to 6.9 -- -- 
Medications Before Pregnancy     
Triptans 21.4 16.1 to 28.5 27.9 3.8 to 
204.9 
Opioids 1.5 1.0 to 2.3 1.2 0.6 to 2.6 
Acetaminophen 1.0 0.8 to 1.3 1.5 0.8 to 3.1 
NSAIDs  0.9 0.7 to 1.2 1.1 0.6 to 2.1 
Anticonvulsants 1.9 0.4 to 8.4 -- -- 
Antidepressants 1.3 0.8 to 2.1 -- -- 
Benzodiazepines  1.6 0.7 to 3.8 -- -- 
Maternal Depression 1.0 0.7 to 1.4 2.2 0.7 to 6.9 
Migraine Type     
With Aura vs Other/Don’t know -- -- 1.1 0.5 to 2.6 
Without Aura vs Other/Don’t know -- -- 1.8 0.8 to 4.1 
Migraine Severity Score (MIGSEV) 1 -- -- 1.2 1.1 to 1.4 
Beliefs About Medicines Questionnaire 
(BMQ): Necessity Subscale 1 
-- -- 1.2 1.1 to 1.3 
Beliefs About Medicines Questionnaire 
(BMQ): Concern Subscale 1 
-- -- 1.1 1.0 to 1.2 
1. Odds of triptan use in pregnancy associated with a one-unit increase in age, MIGSEV score or BMQ score 
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Table 3.4. Comparison of associations between prenatal triptan exposure and 
neurodevelopmental outcome observed with multivariable adjusted, propensity adjusted, and 
propensity matched models 
 β1 95%  
Confidence Interval 
Emotionality, Activity, and Shyness Questionnaire (EAS)  
EAS Sociability   
Unadjusted (MoBa study only) 0.04 -0.07 to 0.15 
Multivariable-adjusted (MoBa study only)2 0.02 -0.10 to 0.14 
PS-adjusted (MoBa study only)3 0.02 -0.10 to 0.14 
PS-matched (MoBa study only)4 0.02 -0.11 to 0.15 
EAS Emotionality   
Unadjusted (MoBa study only) -0.02 -0.14 to 0.10 
Multivariable-adjusted (MoBa study only)2 0.00 -0.13 to 0.13 
PS-adjusted (MoBa study only)3 -0.01 -0.14 to 0.12 
PS-matched (MoBa study only)4 -0.04 -0.18 to 0.09 
EAS Activity   
Unadjusted (MoBa study only) 0.06 -0.06 to 0.17 
Multivariable-adjusted (MoBa study only)2 0.03 -0.09 to 0.16 
PS-adjusted (MoBa study only)3 0.03 -0.09 to 0.16 
PS-matched (MoBa study only)4 0.05 -0.09 to 0.18 
EAS Shyness   
Unadjusted (MoBa study only) 0.08 -0.04 to 0.19 
Multivariable-adjusted (MoBa study only)2 0.05 -0.07 to 0.18 
PS-adjusted (MoBa study only)3 0.05 -0.07 to 0.18 
PS-matched (MoBa study only)4 0.09 -0.04 to 0.22 
Ages and Stages Questionnaire  
(ASQ) 
Odds Ratio1 95%  
Confidence Interval 
ASQ Gross Motor Problems   
Unadjusted (MoBa study only) 0.44 0.16 to 1.20 
Multivariable-adjusted (MoBa study only)2 0.42 0.15 to 1.18 
PS-adjusted (MoBa study only)3 0.46 0.16 to 1.31 
PS-matched (MoBa study only)4 0.54 0.18 to 1.61 
ASQ Fine Motor Problems   
Unadjusted (MoBa study only) 1.37 1.06 to 1.77 
Multivariable-adjusted (MoBa study only)2 1.29 0.97 to 1.72 
PS-adjusted (MoBa study only)3 1.29 0.97 to 1.73 
PS-matched (MoBa study only)4 1.29 0.94 to 1.76 
ASQ Communication Problems   
Unadjusted (MoBa study only) 1.22 0.52 to 2.88 
Multivariable-adjusted (MoBa study only)2 0.96 0.37 to 2.46 
PS-adjusted (MoBa study only)3 1.02 0.41 to 2.53 
PS-matched (MoBa study only)4 0.78 0.28 to 2.14 
1. β is the change in standard deviation units associated with triptan exposure during fetal development, compared to no 
triptan exposure; Odds Ratio is the odds of having one or more delay in each domain associated with triptan exposure, 
relative to no exposure.  
2. Adjusted for maternal age, pre-pregnancy BMI, reproductive history, marital status, maternal education, smoking or 
alcohol use during pregnancy, presence of depressive symptoms, pre-pregnancy triptan use, and co-medication use during 
pregnancy (acetaminophen, opioids, NSAIDs, antidepressants) 
3. Adjusted for the propensity for taking triptans during pregnancy, conditional on maternal age, pre-pregnancy BMI, 
reproductive history, marital status, maternal education, smoking or alcohol use during pregnancy, presence of depressive 
symptoms, pre-pregnancy triptan use, and co-medication use during pregnancy (acetaminophen, opioids, NSAIDs, 
antidepressants) 
4. Each exposed triptan user was matched to two non-users based on propensity score; models were further adjusted for 
factors that remained unbalanced after matching (pregnancy use of opioids and NSAIDs) 
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Table 3.5. Sensitivity analysis: propensity calibration to adjust for migraine type, severity, and 
medication beliefs 
 β 95%  
Confidence 
Interval 
Percent 
Change3 from 
Main PS-
adjusted to 
PSC-adjusted 
models 
Emotionality, Activity, and Shyness 
Questionnaire (EAS) 
   
EAS Sociability    
PS-adjusted (MoBa study only)1 0.02 -0.10 to 0.14  
PSC-adjusted (MoBa and Internet Migraine 
studies)2 
0.01 -0.13 to 0.14 -50.0% 
EAS Emotionality    
PS-adjusted (MoBa study only)1 -0.01 -0.14 to 0.12  
PSC-adjusted (MoBa and Internet Migraine 
studies)2 
-0.01 -0.13 to 0.11 0.0% 
EAS Activity    
PS-adjusted (MoBa study only)1 0.04 -0.08 to 0.17  
PSC-adjusted (MoBa and Internet Migraine 
studies)2 
0.03 -0.11 to 0.17 -25.0% 
EAS Shyness    
PS-adjusted (MoBa study only)1 0.06 -0.07 to 0.19  
PSC-adjusted (MoBa and Internet Migraine 
studies)2 
0.04 -0.06 to 0.18 -33.3% 
Ages and Stages Questionnaire  
(ASQ) 
OR 95%  
Confidence 
Interval 
Percent 
Change3 from 
Main PS-
adjusted to 
PSC-adjusted 
models 
ASQ Gross Motor Delay    
PS-adjusted (MoBa study only)1 0.43 0.15 to 1.22  
PSC-adjusted (MoBa and Internet Migraine 
studies)2 
0.45 0.14 to 1.42 -4.7% 
ASQ Fine Motor Delay    
PS-adjusted (MoBa study only)1 1.28  0.96 to 1.71  
PSC-adjusted (MoBa and Internet Migraine 
studies)2 
1.25 0.89 to 1.74 -2.4% 
ASQ Communication Delay    
PS-adjusted (MoBa study only)1 1.02 0.42 to 2.48  
PSC-adjusted (MoBa and Internet Migraine 
studies)2 
0.93 0.31 to 2.81 9.7% 
1. Adjusted for the propensity for taking triptans during pregnancy, conditional on maternal age, pre-pregnancy BMI, 
reproductive history, marital status, maternal education, smoking or alcohol use during pregnancy, presence of depressive 
symptoms, pre-pregnancy triptan use, and co-medication use during pregnancy (acetaminophen, opioids, NSAIDs, 
antidepressants). PS-adjusted estimates are not IPC-weighted, and so differ slightly from those reported in Table 4. 
2. Adjusted for the propensity for taking triptans during pregnancy (estimate from Table 2.3) and calibrated for migraine 
severity, migraine type, and attitude towards medication (BMQ Necessity and Concern scores), not including BMI and 
antidepressant exposure [inclusion of BMI and antidepressant use in PS did not result in substantial change in β 
estimates] 
3. Percent change calculated as [ (PSCadjusted – PSadjusted) / PSCadjusted ] *100 
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Figure 3.1. Inclusion and exclusion criteria for MoBa Study 
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IV.0 ABSTRACT 
 
Background. Triptans, a class of serotonin agonists, are the most commonly 
used acute antimigraine agent; they readily cross both the placenta and blood-
brain barrier, and are plausible neurodevelopmental teratogens. Studies 
investigating the association between prenatal triptan exposure and 
neurodevelopment in children are sparse. 
Methods. Using data from the Norwegian Mother and Child Cohort Study, a 
prospective birth cohort that includes nearly 40% of all pregnancies in Norway 
from 1999-2008, we identified 50,469 mother-child dyads who met inclusion 
criteria and were present for at least one follow-up assessment at 18 or 36 
months post-partum. Neurodevelopment was assessed using the Child Behavior 
Checklist, the Emotionality, Activity, and Shyness Questionnaire, and the Ages 
and Stages Questionnaire. We used generalized estimating equations to 
evaluate change from 18 to 36 months for children prenatally exposed to triptans, 
relative to contrast groups. 
Results. Among eligible participants (n=50,469), 1.0% used a triptan during 
pregnancy, 2.0% used triptans prior to pregnancy only,  8.0% reported migraine 
without triptan use, and 89.0% had no history of migraine. Children with prenatal 
triptan exposure had greater increases in emotionality (r-RR 2.18, 95%CI 1.03 to 
4.53) and activity problems (r-RR 1.70, 95%CI 1.02 to 2.8) compared to children 
born to mothers who discontinued triptan use prior to pregnancy.  
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Conclusion. Prenatal triptan exposure was associated with emotional and 
behavioral dysregulation.  
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IV.1. Introduction. 
Migraine is a chronic pain condition that affects approximately 20% of 
women of reproductive age.5,6 Treatment options for migraine are primarily 
pharmacologic, and include both preventive medications as well analgesic 
medications, which are taken in response to an oncoming migraine episode. 
Among the analgesic medications, triptans, a class of serotonin 5-HT1B, 5-HT1D 
and 5-HT1F receptor agonists that act on smooth muscle as well as the trigeminal 
cervical complex, are the most common prescription acute migraine medication.9 
To date, 10 studies have examined the safety of triptan use during pregnancy, 
but most have focused on pregnancy and very early life outcomes; triptans have 
been associated with pre-eclampsia, preterm birth, and increased risk of folate-
deficient anemia, but not with major congenital malformations.12,15,37,76 A recent 
meta-analysis found no increased risk of preterm birth or congenital malformation 
associated with prenatal triptan exposure, but did note an increased risk of 
spontaneous abortion;14 an additional review of migraine treatment during 
pregnancy recommends that triptans may be used conservatively in pregnancy, if 
adequate pain relief is not achieved through acetaminophen alone.15 
Studies of the effect of prenatal triptan on childhood neurodevelopment 
have been sparse, and results have been varied. Our previous work has shown 
that prenatal exposure to triptans, particularly in the first trimester, was 
associated with an increased risk of clinically-significant externalizing behavior in 
three year old children,77 and additional work found no associations with motor 
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skills, communication, or temperament, after adjustment for migraine severity.95 
While examination of behavior at a single age is informative, understanding 
trajectories gives a more complete picture of child neurodevelopment. 
Understanding whether groups with prenatal triptan exposure were 
indistinguishable in early childhood but diverge as they progress in age, or 
conversely, had wide differences in early life but converge as they age, may yield 
important insights into the mechanism by which triptans affect the developing 
brain. 
This study aims to quantify the effect of triptan use during pregnancy on 
the differences in neurodevelopment outcomes from 18 to 36 months between 
children.  Among neurodevelopmental outcomes associated with triptan use 
during pregnancy, we also sought to determine whether timing of triptan 
exposure (first trimester, second/third trimester) is related to differences in 
change over time. 
IV.2. Methods. 
Norwegian Mother and Child Cohort Study (MoBa) 
Between 1999 and 2008, the Norwegian Institute of Public Health invited 
women to participate in the Norwegian Mother and Child Cohort Study (MoBa).47 
Women were invited prior to their first routine ultrasound appointment 
(gestational week 13-17). A total of 108,841 women consented to participate 
(participation rate 42.7%), with 84.8% of the participants completing the six 
month post-partum questionnaire and 60.2% completing the 36 month post-
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partum questionnaire.46,78 Written informed consent was obtained from all 
participants, and the Regional Committee for Medical Research Ethics and the 
Norwegian Data Inspectorate approved the study; this analysis was granted an 
exemption from the University of Massachusetts Medical School Institutional 
Review Board. Data were taken from the quality-ensured Data Version 6, 
released by MoBa in 2012 and includes all children born before 2009 for whom 
the age three years questionnaire was received by May 4, 2011; these data were 
linked to the Medical Birth Registry of Norway (MBRN) using participants’ 11-digit 
personal identification numbers. 
Exclusion criteria were: infant not born alive, multiple births, major 
congenital malformations or chromosomal abnormalities, and indication of triptan 
exposure where we were unable to determine whether the triptan was taken prior 
to or during pregnancy. In total, 7,220 women were excluded. We included 
59,468 mother-child dyads with complete outcome data at the 18 and/or 36-
month follow up. We conducted a complete-case analysis in which dyads with 
missing data on variables thought to be confounders were excluded, leaving an 
analytic sample of 50,469 women, of which 14,790 had complete outcome data 
at 18 month follow-up only, 6,774 had complete data only at 36 months, and 
28,905 had complete outcome data at both 18 and 36 months. In analyses of 
timing of triptan exposure, we included only 5,484 women with a self-reported 
history of migraine headache at the first pregnancy questionnaire. Flow through 
the study is further characterized in Figure 4.1. 
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Triptan Exposure 
Information on exposure to medications was gathered prospectively from 
two prenatal (Q1-gestational week17, Q3-gestational week 30) and one 
postpartum questionnaire (Q4-6 months post partum).  Women were asked to 
indicate when they had taken a medication (during the six months before 
pregnancy, during weeks 0-4, 5-8, 9-12, and/or 13 or later for Q1, during weeks 
13-16, 17-20, 21-24, 25-28, and/or week 29 or later for Q3, and from week 30 
until birth for Q4), and to write the name of the medication in a text box.  Women 
who included multiple medications in a single text box (e.g., naratriptan and 
acetaminophen) were assumed to have been exposed to all listed medications in 
all time periods.  Medications were classified according to the World Health 
Organization Anatomical Therapeutic Chemical (ATC) Classification System.48 
The ATC code N02CC was used to determine triptan exposure. Triptan 
medications were further classified into specific compounds: N02CC01 
(sumatriptan), N02CC02 (naratriptan), N02CC03 (zolmitriptan), N02CC04 
(rizatriptan), N02CC05 (almotriptan), N02CC06 (eletriptan), and N02CC07 
(frovatriptan).  No information was available on formulation (tablet vs. injection or 
nasal spray) or dose.  
Information on migraine was gathered prospectively from pregnancy 
questionnaire 1, which asked whether the woman had migraine within 6 months 
prior to pregnancy or during pregnancy, up to the time of filling out the 
questionnaire (approximately week 17 of pregnancy). Four different exposure 
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groups were created based on information about triptan use and migraine before 
and during pregnancy: prenatal triptan exposure, pre-pregnancy triptan use, 
migraine only, and population comparison. It is possible that some women who 
developed migraine later in pregnancy would be incorrectly classified as not 
having migraine: pregnancy questionnaire 3 asks jointly about 
“migraine/headache” rather than specifically about migraine. First onset of 
migraine in pregnancy is rare, and most often occurs in the first trimester,96 and 
so we would expect the number of misclassified women to be low. 
Neurodevelopmental Outcomes 
Child Behavior Checklist (CBCL) 
The Child Behavior Checklist (CBCL) is a validated measure of child 
behavior widely used in both clinical and research practice; a shortened version, 
which has been validated in a Norwegian population, was used in MoBa.52 The 
externalizing (including the “attention problems” and aggressive behavior” 
subscales) and internalizing (including the “emotionally reactive,” 
“anxious/depressed,” and “somatic complaints” subscales) domains were used.  
Standardized z-scores were computed for the study sample; higher z-scores 
indicate more problems within a given domain. We classified scores as being 
clinically meaningful (z-score ≥ 1.50, indicating behaviors more extreme than 
94% of the sample). 
Emotionality Activity and Shyness Temperament Questionnaire (EAS)  
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The Emotionality, Activity, and Shyness Temperament Questionnaire 
measures four temperament domains (emotionality, shyness, sociability, and 
activity). A substantial body of literature has linked early childhood temperament 
to later life depression and other psychiatric diagnoses.79,80 The shortened 
version of the EAS used in the MoBa study, was developed with Norwegian 
social norms in mind, and includes 12 descriptions (e.g. “Your child likes to be 
with people;” “Your child cries easily.”), and parents are asked to rate how well 
each statement applies to their child; in a Norwegian sample, the four factor 
structure of the original scale was reproduced, and internal consistency within 
each scale ranged from α=0.48 to α=0.79.81 We calculated z-scores based on 
the sample distribution of each domain. Higher z-scores indicate greater parental 
endorsement of each temperament trait (e.g. more shy, or more sociable) relative 
to parental reports of other children in the sample. We additionally classified 
scores to indicate temperamental traits more extreme than 94% of the sample (z-
score ≥ 1.50). 
Ages and Stages Questionnaire (ASQ) 
The Ages and Stages Questionnaire is a parent-completed questionnaire 
appropriate for children aged four months to five years. Deficits detected by the 
ASQ have been shown to be predictive of school difficulties in older children,82 
and fine motor skills are highly predictive of later academic achievement.83 The 
abbreviated ASQ used in MoBa includes questions about developmental 
milestone attainment in three major categories: gross motor, fine motor, and 
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communication; this shortened version has been validated in a Norwegian 
population, and had excellent test-retest reliability (94%) and agreement between 
parents and professional examiners, as well as acceptable sensitivity and 
specificity (72% and 86%, respectively)84. Scores on the ASQ domains were 
highly skewed; to address this, we categorized children at each time point as 
having problems in a given domain if they scored at or above the 94th percentile 
in the sample, versus scoring below the 98th percentile. This categorization is 
comparable to using a z-score of 1.5 as a cutoff. 
Concomitant medication use 
We examined other pain medications and psychotropic medications as 
potential confounders, using the following ATC codes: N02BE01 
(acetaminophen), N02A (opioids), M01A (non-steroidal anti-inflammatory drugs, 
NSAIDs), N06A (antidepressants), N05CD02, N05CD03, N05CD08, N05BA01, 
N05BA05, N05BA12 (benzodiazepines), and N03A (anti-epileptics). All co-
medications were categorized as ever vs. never used in pregnancy and prior to 
pregnancy.  
Maternal Characteristics 
Maternal age, pre-pregnancy body mass index (BMI) (underweight or 
<18.5 kg/m2, normal weight or 18.5-25 kg/m2, or overweight, >25 kg/m2 
according to WHO guidelines), education (primary or secondary vs university or 
higher), marital status (married or cohabiting vs other), parity (multiparous vs. 
primiparous) and depression history (yes or no) were all ascertained by self-
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report on Q1. Smoking (ever during pregnancy vs. not during pregnancy) and 
alcohol use (ever during pregnancy vs. not during pregnancy) were ascertained 
by combining information from self-report as well as linkage to the Medical Birth 
Registry of Norway. 
Loss to follow-up 
 We observed substantial attrition at the 18 and 36-month follow-up 
questionnaires. To adjust for the potential for selection bias due to attrition, we 
constructed stabilized inverse probability of treatment weights (IPCW). The 
method for creating IPCW is described in great detail elsewhere;62 briefly, the 
numerator of the stabilized weight is equal to the predicted probability of attrition 
in the sample, and the denominator of the weight is equal to the predicted 
probability of attrition, conditional on measured confounders. In our study, 
maternal age, pre-pregnancy BMI, marital status, reproductive history, migraine 
history, and use of triptans prior to and during pregnancy were included in the 
IPCW. We created IPCW via logistic regression for dropout at 18 and 36 months 
separately, then combined the weights to create a total weight used in further 
analysis.  This method reduces the impact of selection bias on effect estimates 
by ensuring balance of measured predictors of dropout within strata of exposure. 
Statistical Analysis 
The purpose of this analysis was to examine differences in 
neurodevelopmental changes over time that were associated with prenatal triptan 
exposure. Our analysis proceeded in several steps. First, we examined 
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descriptive statistics across the four main exposure groups and compared 
absolute percentages (for categorical measures); we considered a difference 
greater than 5% to be meaningful. Next, we used generalized estimating 
equations (GEE) to fit generalized linear models, specifying a binomial 
distribution and a log link, that included fixed effects for exposure group (prenatal 
triptan exposure, pre-pregnancy triptan use, migraine only, and population 
comparison), time (18 and 36 months), and their interaction. GEE models were 
selected for their approach to missing outcome data (using all available 
observations, rather than case wise deletion for observations present only at a 
single time point), as well as their ability to model covariation using flexible 
covariance structures among repeated measures. Based on comparisons 
between the empirical and model-based covariance matrices, we selected an 
exchangeable covariance structure for all models. The resulting estimates 
represent the change in risk (r-RR) of having a clinically-meaningful 
neurodevelopmental outcome between 18 and 36 months of age for children with 
prenatal triptan exposure, relative to each contrast group (pre-pregnancy triptan 
use only, migraine only, and population comparison), with 95% confidence 
intervals (CI) calculated using robust standard errors. Models were adjusted for 
maternal characteristics (age, pre-pregnancy BMI, parity, marital status, 
education, smoking or alcohol use in pregnancy, depression symptom severity) 
and concomitant medication use (NSAIDs, acetaminophen, opioids, 
antidepressants). To assist in the interpretation of the data, we used model-
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based predicted probability of outcome at 18 and 36 months to create line graphs 
of the change in outcome over time for each exposure group. Examination of 
graphs were useful because an r-RR greater than 1 could be a result of 
qualitatively different phenomena (e.g. greater increased risk over time in triptan 
group relative to increased risks observed in the contrast group, increased risk in 
the triptan users group and decreased risk in the comparison group, etc.).  
Second, for the neurodevelopmental outcomes which appeared to be 
associated with any triptan use during pregnancy, we developed marginal 
structural models (MSM) to understand the effect of exposure timing on the 
difference in change of the outcome from 18 to 36 months. We fit marginal 
structural models (MSM) with stabilized inverse probability of treatment weights 
(IPTW) to adjust for measured confounding by baseline characteristics (maternal 
age, pre-pregnancy BMI, sociodemographic variables), time-invariant predictors 
(smoking and alcohol use during pregnancy, folate supplementation, maternal 
depression severity) as well as time-varying confounders (other medication use, 
including acetaminophen, NSAIDs, opioids, and antidepressants). The MSM 
approach results in unbiased effect estimates under assumptions of 
exchangeability and positivity, and allows for appropriate adjustment for the 
effects of confounders that are also mediators.59,97 We created the IPTW via 
logistic regression at each exposure time point (pre-pregnancy, first trimester, 
second/third trimester) created an IPTW equal to the product of the weight from 
each time point. The product of the IPTW and IPCW was used as the total MSM 
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weight, to account for both measured confounding and loss to follow-up. Weights 
were examined for extreme values. After identifying a small number of extreme 
weights (>32) in women who had no history of triptan use prior to second/third 
trimester initiation, we elected to truncate weights at the 99th percentile. Weighted 
GEE models were then fit within the migraine-only group. Results are given as 
the change in risk ratio over time (r-RR) for triptan exposure at each time point 
(pre-pregnancy, first trimester, second/third trimester) relative to no exposure 
during that time, with 95% confidence intervals estimated using robust standard 
errors to account for clustering induced by weighting. 
For analyses conducted in the first and second steps, we interpreted a 
significant time-by-group interaction (95% confidence interval that did not include 
1) to be indicative of a difference in change between exposure groups, from 18 to 
36 months of follow-up. 
 
IV.3. Results. 
After applying study inclusion and exclusion criteria, 50,469 women were 
included, of whom 1.0% reported using a triptan at least once during pregnancy, 
2.0% used triptans prior to pregnancy only, and 8.0% had a history of migraine 
with no use of triptans. Among the 5,484 women with history of migraine (10.9% 
of the total sample), 27.1% used triptans prior to pregnancy, 6.9% reported use 
during the first trimester, and 3.1% reported use during the second or third 
trimester. 
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 Women who reported triptan use during pregnancy differed little from 
comparison groups in demographic characteristics: age, pre-pregnancy BMI, 
parity, educational attainment, smoking during pregnancy, and folate 
supplementation were similar across groups.  However, women who used triptan 
during pregnancy had higher mean depression and anxiety symptom scores than 
women who discontinued triptan use (0.16 vs. 0.03). In addition, women with 
triptan use during pregnancy were more likely to use other medications at higher 
rates during pregnancy compared to women who discontinued triptan use, 
including opioids (13.3% vs. 4.6%), acetaminophen (78.2% vs. 69.8%), and 
NSAIDs (22.0% vs. 10.1%). Further characteristics of the study sample are 
described in Table 4.1. 
The Externalizing Behaviors subscale of the CBCL, as well as the 
Emotionality and Activity subscales of the EAS, describe a set of behaviors 
characterized by increased activity, aggression, and emotional reactivity. 
Children whose mothers used triptans during pregnancy had substantial 
increased risk of high emotionality, compared to static or decreased emotionality 
in children whose mothers used triptans only prior to pregnancy (r-RR 2.18, 
95%CI 1.03 to 4.53) as well as those with a history of migraine without triptan 
use (r-RR 2.51, 95%CI 1.27 to 4.90) and a migraine-free population comparison 
group (r-RR 2.16, 95%CI 1.14 to 2.14) (Table 4.2, Figure 4.2). When we 
examined the association between timing of triptan exposure within the group of 
women with migraine using marginal structural models (MSM) with inverse 
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probability weights (IPW), the r-RR estimate for first trimester exposure relative to 
no first trimester exposure was 1.54 (95%CI 0.57 to 4.13) and the r-RR estimate 
for second/third trimester exposure relative to no second/third trimester exposure 
was  2.41 (95%CI 0.71 to 8.20) (Table 4.3). We also observed differences in rate 
of change for activity: children with prenatal triptan exposure had lesser 
decreases in activity from 18 to 36 months, relative to the pre-pregnancy (r-RR 
1.70, 95%CI 1.02 to 2.80), migraine-only (r-RR 1.57, 95%CI 1.04 to 2.36), and 
population comparison (r-RR 1.67, 95%CI 1.14 to 2.14) groups (Table 4.2). 
Examining the association between timing of exposure, the r-RR estimate for first 
trimester exposure relative to no first trimester exposure was 1.98 (95%CI 0.90 to 
4.34) and the r-RR estimate for second/third trimester exposure relative to no 
second/third trimester exposure was 1.37 (95%CI 0.46 to 4.10) (Table 4.3). 
Externalizing behavior in children with prenatal triptan exposure, as measured by 
the CBCL, remained elevated compared to all contrast groups, but did not show 
evidence of increase or decrease over time (Table 4.2, Figure 4.2). 
The Internalizing Behavior subscale of the CBCL, along with the Shyness 
and Sociability subscales of the EAS, describe a set of symptoms characterized 
by anxiety, shyness, and withdrawal. Change in shyness and sociability were not 
associated with use of triptans during pregnancy (Table 4.2, Figure 4.3). We saw 
no differences in change of risk for gross motor, fine motor, or communication 
problems from 18 to 36 months for children with prenatal triptan exposure, 
relative to any comparison group (Table 4.2, Figure 4.3). 
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IV.4. Discussion. 
We observed several neurodevelopmental domains in which change in 
neurodevelopment was substantially different for children with prenatal triptan 
exposure, including emotionality and activity; these domains appear to be 
associated with prenatal triptan exposure specifically, rather than migraine alone. 
There were no overall differences in internalizing behaviors and shyness and 
motor problems or communication problems associated with either triptan 
exposure or migraine. 
Our previous work, which was the first to report on neurodevelopmental 
sequelae of prenatal triptan exposure, indicated that exposed children had higher 
rates of externalizing problems at 36 months than those without prenatal 
exposure.77 The findings from the current study suggest that these elevated rates 
of externalizing behavior remain relatively stable between 18 and 36 months; 
additionally, the observed increases in emotionality and activity describe a 
consistent profile of temperamental and behavioral dysregulation associated with 
prenatal triptan exposure. 
A possible alternative explanation for our findings is that the triptan group 
identified in our study should be thought of as proxies for migraine severity, with 
the women who used triptans in pregnancy having the most severe migraine, 
women who discontinued triptan use prior to pregnancy as having less severe 
illness, and women with migraine who did not use triptans as being the least 
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severe. If this were the case, we might expect to see the prenatal exposure and 
pre-pregnancy only comparison group showing the smallest effect size, followed 
by increasing effect magnitude for contrasts with the migraine-only and 
population comparison groups. However, our results showed relatively stable 
effect sizes for prenatal triptan exposure compared to all contrast groups. 
Overall, our results suggest a distinct profile for children with prenatal exposure 
to triptans in which changes in externalizing-type behaviors from 18 to 36 months 
were markedly different from all comparison groups..  
Misclassification of triptan exposure may also explain our findings. 
Maternal report of analgesic medication use in pregnancy has been shown to 
have low sensitivity but high specificity,50 suggesting that while reported 
medication use in pregnancy is likely to be accurate, some women have been 
inaccurately classified as unexposed. The MoBa study collects exposure data 
prospectively, and so exposure misclassification is likely to be nondifferential; 
however, if maternal anxiety is associated with differences in reporting of 
medication exposure, it is possible that misclassification of exposure, with its 
associated unpredictable biases, could be driving the effect estimates for 
prenatal triptan exposure. Similarly, it is possible that women classified as pre-
pregnancy triptan users were in fact early first trimester users instead. If this 
misclassification is non-differential, it could also be a source of bias. 
The prevalence of externalizing problems among children with prenatal 
triptan exposure were elevated at 18 months and remained relatively stable at 36 
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months, while prevalence of emotionality and activity both increased from 18 to 
36 months in children with prenatal exposure, compared to all contrast groups. 
Emotionality, in the context of the Emotionality, Activity, and Shyness 
Questionnaire includes items that tap emotional reactivity, while items in the 
Activity subscale ask about higher levels of physical activity. Of potential interest 
is that fact that the emotionality and activity domains, as well as the externalizing 
behavior domain, ask parents to report on observable behaviors in their children, 
such as temper explosions, hyperactivity, and coordination problems, while the 
sociability and shyness domains, as well as internalizing behaviors, ask parents 
to report on their child’s internal state. Parents are better reporters of 
externalizing symptoms while children are better reporters of internalizing 
symptoms.98 Future studies should include replicating these findings in an older 
cohort of children, in which child self-report of psychological or behavioral 
problems is available. 
The results of this study have important clinical implications for prescribers 
treating women with migraine during pregnancy. A recent review of migraine 
treatment during pregnancy has recommended that triptans may be used 
conservatively during pregnancy, if other therapies such as acetaminophen do 
not provide adequate pain relief;15 in addition, a recent meta-analysis of triptan 
use in pregnancy found that prenatal triptan use was associated with an 
increased risk of spontaneous abortion, although not of preterm birth or 
congenital malformations.14 The current study expands the potentially-negative 
   
 100 
outcomes that may result from prenatal triptan use, and providers who treat 
pregnant women with migraine should consider the risks accordingly. There are 
also implications for clinicians who may see children born to mothers with 
migraine headache.  Numerous studies have shown that early childhood 
emotional and behavioral problems are predictive of academic and emotional 
difficulties in adolescence,29,39,51,99 but that early intervention can effectively 
reduce these problems.100,101 Children whose mothers have a history of migraine, 
and particularly those whose mothers took triptans during pregnancy, may 
benefit from additional monitoring and potentially, treatment.   
There are several important limitations to consider when evaluating the 
findings from this study. First, MoBa does not collect information on migraine 
severity. Our previous work has shown that women with more severe migraine 
are more likely to take triptans during pregnancy,95 although subsequent 
adjustment for migraine severity resulted in modest changes in effect estimates. 
Confounding by indication is difficult to control,26 and cannot be ruled out as an 
alternative explanation for the observed results. Second, no information was 
available on triptan formulation or dose; additionally, we had insufficient power to 
analyze specific triptans. Triptans have different pharmacokinetic properties and 
differing affinities for subclasses of serotonin receptors,102 and considering these 
medications as a class, without consideration for dose or formulation, may elide 
important information on risks specific to individual compounds. 
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These limitations are balanced by important strengths: first, we used 
advanced analytic methods to appropriately adjust for time-varying confounding 
by concomitant medication use. Triptan exposure changes over time, and women 
who use triptans in pregnancy also use many other medications, several of which 
have previously been associated with neurodevelopmental problems in 
children.30,31,103 Failure to appropriately adjust for these medications may result in 
incorrectly attributing effects to triptan exposure that are in fact due to other 
medications. Our study was set in a large, prospective birth cohort with data 
available on both over the counter and prescription medication use, allowing for 
careful consideration of concomitant medication use, as well as other important 
confounders such as severity of maternal depressive and anxiety symptoms. 
Taken together, the findings from this study suggest that fetal exposure to 
triptans is associated with a set of traits related to emotional and behavioral 
dysregulation. In light of this and other recent studies, we recommend caution in 
the use of triptan medications during pregnancy, until future research clarifies the 
role of the underlying migraine. 
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Table 4.1. Maternal and pregnancy characteristics 
 Migraine No Migraine 
 Triptans in 
pregnancy 
Triptans prior 
to pregnancy 
No triptan 
history 
Population 
Comparison 
 N=495 N=1,002 N=4,050 N=44,922 
Age in years (Mean, SD) 30.9(4.3) 30.4(4.1) 30.2(4.5) 30.3(4.4) 
Body Mass Index (kg/m2)     
<18.5 12(2.4) 25(2.5) 145(3.6) 1,216(2.7) 
18.5-25 307(62.0) 608(60.7) 2,491(61.5) 29,747(66.2) 
>25 176(35.6) 369(36.8) 1,414(34.9) 13,959(31.1) 
Multiparous  254(51.3) 467(46.6) 2,204(54.4) 24,467(54.5) 
Married or cohabitating  474(95.8) 980(97.8) 3,922(96.8) 43,761(97.4) 
Mother Education     
Primary or secondary 165(33.3) 339(33.8) 1,533(37.9) 14,511(32.3) 
University or higher 330(66.7) 663(66.2) 2,517(62.2) 30,411(67.7) 
Smoking during pregnancy 57(11.5) 118(11.8) 552(13.6) 5,236(11.7) 
Alcohol during pregnancy 95(19.2) 146(14.6) 623(15.4) 7,506(16.7) 
Folate Supplementation  299(60.4) 618(61.7) 2,359(58.3) 26,462(58.9) 
Multivitamin Supplementation  186(37.6) 426(42.5) 1,610(39.8) 16,661(37.1) 
Migraine Preventive Therapy 8(1.6) 21(2.1) 22(0.5) 0(0.0) 
Opioids     
Pre-pregnancy 40(8.1) 52(5.2) 208(5.1) 609(1.4) 
In pregnancy 66(13.3) 46(4.6) 188(4.6) 631(1.4) 
Paracetamol/acetaminophen     
Pre-pregnancy 233(47.1) 475(47.4) 1,794(44.3) 11,474(25.5) 
In pregnancy 387(78.2) 699(69.8) 2,596(34.1) 19,331(43.0) 
NSAIDs     
Pre-pregnancy 109(22.0) 247(24.7) 938(23.1) 4,450(9.9) 
In pregnancy 109(22.0) 101(10.1) 509(12.6) 2,652(5.9) 
Antidepressants     
Pre-pregnancy 24(4.9) 48(4.8) 158(3.9) 1,042(2.3) 
In pregnancy 11(2.2) 11(1.1) 67(1.7) 426(1.0) 
Anti-convulsants     
Pre-pregnancy 2(0.4) 7(0.7) 10(0.3) 41(0.1) 
In pregnancy 1(0.2) 3(0.3) 13(0.3) 86(0.2) 
Benzodiazepines     
Pre-pregnancy 8(1.6) 13(1.3) 38(0.9) 240(0.5) 
In pregnancy 8(1.6) 5(0.5) 19(0.5) 165(0.4) 
Maternal depressive/anxiety 
symptoms1 (Mean, SD) 
0.16(1.70) 0.03(1.84) 0.23(1.88) -0.12(1.63) 
Pre-eclampsia 33(6.7) 47(4.7) 170(4.2) 1,536(3.4) 
Small for Gestational Age 35(7.1) 65(6.5) 269(6.6) 2,737(6.1) 
Apgar 5 (<7) 7(1.4) 9(0.9) 30(0.7) 415(0.9) 
Preterm 19(3.8) 45(4.5) 193(4.8) 2,026(4.5) 
Low Birth Weight 11(2.2) 24(2.4) 108(2.7) 1047(2.3) 
1. Average z-score from the Symptom Checklist (SCL); higher positive scores indicate more depressive 
symptoms 
 
 
 
 
 
   
 
1
0
3
      
Table 4.2. Change in neurodevelopmental outcome from 18 to 36 months: change over time for prenatal triptan exposure, 
relative to pre-pregnancy triptan use, migraine-only, and population comparison  
  Unadjusted Multivariable Adjusted3 
 Percent18m1 Percent 36m rRR2 95% Confidence Interval rRR 95% Confidence Interval 
CBCL Externalizing Behavior       
Prenatal Triptan Use 11.0 10.0     
   Vs. Pre-pregnancy triptans only 7.8 6.5 1.11 0.70 to 1.73 1.11 0.70 to 1.75 
   Vs. Migraine only 8.1 7.6 0.99 0.69 to 1.43 1.00 0.70 to 1.43 
   Vs. Population comparison 7.7 6.5 1.11 0.79 to 1.54 1.11 0.79 to 1.54 
EAS Emotionality       
Prenatal Triptan Use 3.2 6.3     
Vs. Pre-pregnancy triptans only 5.3 4.7 2.18 1.03 to 4.57 2.18 1.03 to 4.53 
   Vs. Migraine only 5.1 3.9 2.51 1.28 to 4.90 2.51 1.27 to 4.90 
   Vs. Population comparison 5.2 4.7 2.18 1.14 to 4.10 2.16 1.14 to 4.10 
EAS Activity       
Prenatal Triptan Use 9.2 8.3     
Vs. Pre-pregnancy triptans only 9.7 4.7 1.68 1.02 to 2.80 1.70 1.02 to 2.80 
   Vs. Migraine only 9.8 5.3 1.57 1.05 to 2.34 1.57 1.04 to 2.36 
   Vs. Population comparison 9.8 5.1 1.67 1.14 to 2.41 1.67 1.14 to 2.42 
CBCL Internalizing Behavior       
Prenatal Triptan Use 8.1 9.5     
Vs. Pre-pregnancy triptans only 6.2 10.8 0.70 0.41 to 1.16 0.69 0.41 to 1.14 
   Vs. Migraine only 8.7 10.5 1.01 0.66 to 1.57 1.02 0.66 to 1.57 
   Vs. Population comparison 7.5 8.1 1.14 0.75 to 1.72 1.12 0.74 to 1.70 
EAS Shyness       
Prenatal Triptan Use 4.9 12.3     
Vs. Pre-pregnancy triptans only 3.5 9.6 0.93 0.53 to 1.65 0.92 0.52 to 1.63 
   Vs. Migraine only 4.0 7.7 1.30 0.81 to 2.08 1.30 0.81 to 2.08 
   Vs. Population comparison 4.5 8.1 1.40 0.91 to 2.16 1.40 0.91 to 2.16 
EAS Sociability       
Prenatal Triptan Use 8.8 6.3     
Vs. Pre-pregnancy triptans only 6.8 6.4 0.77 0.45 to 1.38 0.78 0.44 to 1.38 
   Vs. Migraine only 9.3 6.1 1.12 0.69 to 1.80 1.13 0.70 to 1.82 
   Vs. Population comparison 8.0 5.7 1.02 0.65 to 1.62 1.03 0.65 to 1.63 
1. Percent is the percent with outcome, respectively, at each measurement (18 and 36 months post-partum)  
2. rRR(ratio of risk ratios) is the group-by-time interaction coefficient from the generalized estimating equation model; it is the difference in change from 18 to 36 months for 
prenatal triptan exposure, relative to each contrast group   
3. Models are adjusted for maternal age, pre-pregnancy body mass index, parity, marital status, education, smoking or alcohol use during pregnancy, Symptom Checklist 
depression/anxiety severity score, and concomitant medication use during pregnancy (acetaminophen, opioids, NSAIDs, antidepressants).  
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Table 4.2. (continued) 
  Unadjusted Multivariable Adjusted3 
 Percent18m1 Percent 36m rRR2 95% Confidence 
Interval 
rRR 95% Confidence 
Interval 
ASQ Gross Motor       
Prenatal Triptan Use 1.6 1.2     
Vs. Pre-pregnancy triptans only 3.3 3.0 0.86 0.23 to 3.20 0.86 0.23 to 3.19 
   Vs. Migraine only 2.3 3.0 0.58 0.16 to 2.02 0.58 0.17 to 2.03 
   Vs. Population comparison 2.3 3.1 0.55 0.16 to 1.87 0.55 0.16 to 1.88 
ASQ Fine Motor       
Prenatal Triptan Use 13.9 9.5     
Vs. Pre-pregnancy triptans only 11.6 9.4 0.84 0.52 to 1.36 0.85 0.52 to 1.37 
   Vs. Migraine only 11.5 9.2 0.85 0.56 to 1.28 0.85 0.56 to 1.29 
   Vs. Population comparison 11.8 10.4 0.78 0.52 to 1.13 0.77 0.52 to 1.14 
ASQ Communication       
Prenatal Triptan Use 3.4 4.6     
Vs. Pre-pregnancy triptans only 4.1 4.5 1.20 0.55 to 2.64 1.22 0.56 to 2.68 
   Vs. Migraine only 3.8 5.2 0.96 0.48 to 1.93 0.97 0.48 to 1.95 
   Vs. Population comparison 4.1 5.0 1.09 0.56 to 2.16 1.12 0.57 to 2.19 
1. Percent is the percent with outcome, respectively, at each measurement (18 and 36 months post-partum) 
2. rRR(ratio of risk ratios) is the group-by-time interaction coefficient from the generalized estimating equation model; it is the difference in change from 18 to 36 months for 
prenatal triptan exposure, relative to each contrast group. 
3. Models are adjusted for maternal age, pre-pregnancy body mass index, parity, marital status, education, smoking or alcohol use during pregnancy, Symptom Checklist 
depression/anxiety severity score, and concomitant medication use during pregnancy (acetaminophen, opioids, NSAIDs, antidepressants 
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Table 4.3. Change in neurodevelopmental outcome from 18 to 36 months: change over time associated with timing of triptan 
exposure, within migraine-only sample (N=5,484)  
   Unadjusted MSM3 
 Percent18m1 Percent 36m rRR2 95% Confidence 
Interval 
rRR 95% Confidence 
Interval 
CBCL Externalizing Behavior      
Pre-pregnancy 8.4 7.5 0.94 0.67 to 1.30 0.90 0.64 to 1.25 
First Trimester 11.6 11.1 1.16 0.73 to 1.86 1.01 0.56 to 1.80 
Second/Third Trimester 10.7 9.8 0.96 0.48 to 1.91 0.50 0.17 to 1.48 
EAS Emotionality       
Pre-pregnancy 4.7 4.7 1.07 0.69 to 1.67 1.07 0.68 to 1.67 
First Trimester 3.8 5.6 1.43 0.58 to 3.51 1.54 0.57 to 4.13 
Second/Third Trimester 4.0 7.1 1.52 0.48 to 4.85 2.41 0.71 to 8.20 
EAS Activity       
Pre-pregnancy 9.6 5.7 0.90 0.63 to 1.28 0.88 0.61 to 1.28 
First Trimester 9.3 8.9 1.56 0.90 to 2.71 1.98 0.90 to 4.34 
Second/Third Trimester 9.4 10.7 1.56 0.76 to 3.21 1.37 0.46 to 4.10 
1. Percent is the percent with outcome at each measurement (18 and 36 months post-partum), among those with exposure at each time point (e.g.: Percent with 
externalizing problems at 18 months with prenatal triptan use ={ [75 / 1002] *100 }= 7.49%; percent with gross motor problems at 36 months with first trimester triptan use ={ 
[56 / 270] *100 }= 20.74%. Windows of triptan exposure are not mutually exclusive). 
2. rRR (ratio of risk ratios) is the group-by-time interaction coefficient from the generalized estimating equation model; it is the difference in change from 18 to 36 months for 
each group, relative to no exposure during that time point. 
3. Models are weighted by the product of stabilized inverse probability of censoring weight (IPCW) and inverse probability of treatment weight (IPTW); IPCW is the probability 
of dropout, conditional on maternal age, pre-pregnancy BMI, marital status, parity, migraine history, use of triptans prior to and during pregnancy. IPTW includes baseline 
covariates (maternal age, pre-pregnancy BMI, sociodemographic variables), time-invariant predictors (smoking and alcohol use during pregnancy, folate supplementation, 
maternal depression severity), time-varying concomitant medication use (acetaminophen, NSAIDs, opioids, antidepressants), and treatment history (triptan use). 
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Figure 4.1. Inclusion and exclusion criteria and flow through study 
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Figure 4.2. Changes in externalizing behavior, emotionality, and activity from 18 to 36 
months  
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Figure 4.3. Changes in internalizing behavior, shyness, and sociability from 18 to 36 
months 
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Figure 4.4. Changes in fine motor, gross motor, and communication from 18 to 36 
months 
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CHAPTER V 
 
DISCUSSION AND CONCLUSIONS 
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V.1. Summary of findings 
This dissertation project set out to examine the association between 
prenatal exposure to triptan medications and a spectrum of neurodevelopmental 
outcomes in children, using causal inference methods in order to address 
methodological challenges that are specific to triptans. Triptan exposure during 
fetal development has been linked to several pregnancy and delivery 
outcomes,14,15 but no previous studies have examined the association between 
prenatal triptan exposure and differences in neurodevelopment in children. 
Triptans are serotonin 1B, 1D, and 1F receptor agonists, which are involved in 
fetal brain development, particularly for subcortical structures and projections 
from subcortical structures to neocortex.18,19 We hypothesized that children 
exposed to triptans during fetal development would exhibit neurodevelopmental 
differences from children without prenatal triptan exposure. 
In the first aim, we first compared the risk of internalizing and externalizing 
behaviors in children with prenatal triptan exposure to each of three comparison 
groups: children whose mothers discontinued triptan use prior to pregnancy, 
children whose mothers reported a history of migraine with no triptan use before 
or during pregnancy, and a population comparison group with no history of 
migraine or triptan use. We observed that at 36 months of age, children with 
prenatal triptan exposure had a substantially higher risk of clinically meaningful 
externalizing problems compared to all comparison groups, after adjustment for 
multiple potential confounders including maternal characteristics and concomitant 
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medication use; we observed no association between triptan exposure and 
internalizing symptoms. In order to determine whether these risks were specific 
to timing of exposure, we conducted further analyses using marginal structural 
models. These analyses yielded several important findings. First, the risk of 
externalizing behaviors was associated primarily with first trimester triptan 
exposure. Second, in examining timing of triptan exposure and internalizing 
symptoms, we found that in traditional multivariable adjusted models, pre-
pregnancy exposure was associated with an increased risk of internalizing 
symptoms, but that use of marginal structural models, which correctly adjust for 
time-varying confounding using weighting methods, this risk was attenuated. 
These analyses were limited, however, by our inability to adjust for several 
potentially important confounders which were unmeasured in MoBa, including 
migraine type and severity, as well as maternal attitudes towards medication use.  
In order to address the limitations of first study, in the second dissertation 
aim, we made use of an external validation study that contained information 
these important confounders, and used propensity score calibration to adjust our 
effect estimates. The outcomes included in the second study were: temperament 
characteristics (emotionality, activity, shyness, and sociability), psychomotor 
function, and communication skills. We found that migraine severity and maternal 
attitudes towards medication use were associated with triptan use during 
pregnancy, but that migraine type (with or without aura) was not. In this second 
study, prenatal triptan use was not associated with differences in temperament, 
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psychomotor function, or communication skills; however, even within the context 
of an essentially null study, propensity score calibration resulted in a reduction in 
bias of effect estimates of between 5—50%, suggesting that migraine severity 
and maternal attitudes towards medication use play an important role in the 
association between prenatal triptan exposure and neurodevelopment. 
Recognizing that neurodevelopment is by definition a dynamic process, in 
the third aim, we examined changes in neurodevelopmental outcomes between 
18 and 36 months of age in children with prenatal triptan exposure compared to 
children whose mothers discontinued triptan use prior to pregnancy, those whose 
mothers had migraine without a history of triptan use, and a population 
comparison group. We also examined longitudinal changes associated with time-
varying triptan exposure amongst migraineurs only. Examining longitudinal 
changes revealed additional differences in exposure groups that were not 
apparent when children were examined only at 36 months. While externalizing 
behavior remained elevated from 18 to 36 months, we observed sharply different 
development in emotionality and activity for prenatally exposed children relative 
to all comparison groups. Timing of exposure was not as specific as we observed 
in the first dissertation aim: rather, exposure during either first or second/third 
trimesters was associated with differences in change from 18 to 36 months, 
although with wide confidence intervals that included 1.  
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V.2. Clinical implications 
 The findings from this dissertation have several implications that could 
affect providers’ clinical management of women who suffer from migraine 
headache during pregnancy. Previous research focused on pregnancy and 
delivery outcomes has found an increased risk of spontaneous abortion 
associated with triptan use during pregnancy,14 as well as inconsistent 
associations with preterm birth, pre-eclampsia, and atonic uterus.12,37 Our work 
suggests that risks associated with prenatal triptan exposure extend into 
childhood, and should be considered carefully when recommending treatment 
options to pregnant women suffering from migraine. These risks should be 
considered in the context of our, and others’, findings that migraine itself carries 
additional risks. 
 While studies have shown that children with emotional and behavioral 
problems in early childhood often go on to have academic, social, and psychiatric 
problems in adolescence,29,51,99 evidence suggests that early intervention can be 
successful at ameliorating these risks.100,101 Understanding that prenatal triptan 
exposure is a risk factor for emotional and behavioral problems should help to 
identify children who could benefit from these early interventions. 
V.3. Research implications 
 Awareness of increased medication use during pregnancy has led to 
increasing attention being paid to the safety of medication use during pregnancy, 
and the number of studies on this topic has increased sharply in the past decade 
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 Second, we found that women who used triptans during pregnancy also 
reported the use of many other medications, including several medication 
classes that have previously been linked to neurodevelopmental problems in 
exposed children.30,31,42–44 Similarly, appropriate modeling of medication use, 
particularly for medications that are used episodically as triptans are, is essential 
to obtaining unbiased effect estimates for the risk of medication exposure on 
pregnancy, delivery, and childhood outcomes. This is especially important when 
the medication of interest is used in conjunction with other medications, or co-
occurs with other potentially harmful exposures. 
V.4. Limitations and strengths 
 Several important limitations indicate that our results should be interpreted 
with some caution. Selection bias, in the form of high attrition at the 18 and 36-
month post-partum follow-up assessment, can result in unpredictable bias of 
effect estimates, depending on the reasons for attrition. We used inverse 
probability of censoring weights to adjust our effect estimates for measured 
predictors of attrition, but residual bias due to unmeasured predictors of attrition 
is still possible. Relatedly, we used causal inference methods, including marginal 
structural models and propensity score methods, which make a strong 
assumption of no unmeasured confounding, which was violated in our study. In 
addition, while we applied multiple analytic approaches and sensitivity analyses 
to indirectly control the effects of confounding by migraine severity, and 
concluded that confounding by migraine severity would have to be unrealistically 
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strong in order to fully explain our observed effect estimates, we ultimately 
cannot rule out confounding by indication as an explanation for our results. 
Finally, despite an initial large sample size, the rarity of triptan exposure in this 
study meant that we had insufficient power to examine specific triptans, and so 
analyzed all triptan together as a class. Given differences in formulations, 
receptor affinity, and pharmacokinetic properties of various triptan 
medications,102 it is possible that individual triptans have differences in safety 
profiles during pregnancy, which we could not examine in this study.   
 Despite these limitations, this dissertation has several notable strengths 
that make it a valuable contribution to the literature on the safety of triptan 
medication exposure during pregnancy. The studies were conducted within the 
Norwegian Mother and Child Cohort Study (MoBa), a large, prospective birth 
cohort that includes more than 100,000 mother-child dyads followed from their 
first ultrasound visit and into childhood.47 MoBa includes detailed information on 
medication use during pregnancy, for both prescription and over-the-counter 
medications. In addition, we used sensitive, psychometrically validated 
instruments as outcome measures that capture multiple dimensions of child 
neurodevelopment, including behavior, temperament, psychomotor development, 
and communication skills. These outcome measures are an improvement over 
relying on diagnostic codes in the medical record, as the instruments capture 
neurodevelopmental problems that may not yet rise to the level of a diagnosis, 
particularly in very young children. Finally, we applied several advanced analytic 
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techniques, including marginal structural models and propensity matching and 
calibration, which allowed us to obtain less-biased effect estimates than we 
would have observed using traditional methods. The findings of this dissertation 
should be interpreted with these strengths and limitations in mind. 
V.5. Final Conclusions 
Taken together, the findings from this dissertation suggest that prenatal 
triptan exposure is associated with consistently elevated externalizing-type 
behaviors and symptoms, and that these risks are most pronounced for first 
trimester exposure. While we cannot rule out confounding by indication as an 
explanation for these findings, our analysis suggests that the effects of migraine 
severity would have to be extremely strong to fully explain our findings. In light of 
these results, and also considering previous research,14 we recommend that 
triptans be used during pregnancy only if other analgesics do not provide 
adequate pain relief, and the effects of migraine (nausea, anorexia) are 
themselves resulting in fetal harm. Future studies should include measures of 
migraine severity throughout pregnancy, in order to better discern the role of 
confounding by indication. 
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